| Year |
Citation |
Score |
| 2021 |
Fizazi K, González Mella P, Castellano D, Minatta JN, Rezazadeh Kalebasty A, Shaffer D, Vázquez Limón JC, Sánchez López HM, Armstrong AJ, Horvath L, Bastos DA, Amin NP, Li J, Unsal-Kacmaz K, Retz M, et al. Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial. European Journal of Cancer (Oxford, England : 1990). PMID 34802864 DOI: 10.1016/j.ejca.2021.09.043 |
0.465 |
|
| 2021 |
Schmidt AL, Tucker MD, Bakouny Z, Labaki C, Hsu CY, Shyr Y, Armstrong AJ, Beer TM, Bijjula RR, Bilen MA, Connell CF, Dawsey SJ, Faller B, Gao X, Gartrell BA, et al. Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19. Jama Network Open. 4: e2134330. PMID 34767021 DOI: 10.1001/jamanetworkopen.2021.34330 |
0.401 |
|
| 2021 |
Patierno BM, Foo WC, Allen T, Somarelli JA, Ware KE, Gupta S, Wise S, Wise JP, Qin X, Zhang D, Xu L, Li Y, Chen X, Inman BA, McCall SJ, ... ... Armstrong AJ, et al. Characterization of a castrate-resistant prostate cancer xenograft derived from a patient of West African ancestry. Prostate Cancer and Prostatic Diseases. PMID 34645983 DOI: 10.1038/s41391-021-00460-y |
0.431 |
|
| 2021 |
Penson DF, Armstrong AJ, Concepcion RS, Agarwal N, Olsson CA, Karsh LI, Dunshee CJ, Duggan W, Shen Q, Sugg J, Haas GP, Higano CS. Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial. Prostate Cancer and Prostatic Diseases. PMID 34621011 DOI: 10.1038/s41391-021-00465-7 |
0.461 |
|
| 2021 |
Tombal BF, Freedland SJ, Armstrong AJ, Beer TM, Stenzl A, Sternberg CN, Hussain M, Ganguli A, Ramaswamy K, Bhadauria H, Ivanescu C, Turnbull J, Holmstrom S, Saad F. Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials. Prostate Cancer and Prostatic Diseases. PMID 34518652 DOI: 10.1038/s41391-021-00447-9 |
0.34 |
|
| 2021 |
Azad AA, Armstrong AJ, Alcaraz A, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Alekseev B, Iguchi T, Shore ND, Gomez-Veiga F, Rosbrook B, Lee HJ, Haas GP, Stenzl A. Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk. Prostate Cancer and Prostatic Diseases. PMID 34420037 DOI: 10.1038/s41391-021-00436-y |
0.386 |
|
| 2021 |
Koshkin VS, Patel VG, Ali A, Bilen MA, Ravindranathan D, Park JJ, Kellezi O, Cieslik M, Shaya J, Cabal A, Brown L, Labriola M, Graham LS, Pritchard C, Tripathi A, ... ... Armstrong A, et al. PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 34363009 DOI: 10.1038/s41391-021-00433-1 |
0.437 |
|
| 2021 |
Sperger JM, Emamekhoo H, McKay RR, Stahlfeld CN, Singh A, Chen XE, Kwak L, Gilsdorf CS, Wolfe SK, Wei XX, Silver R, Zhang Z, Morris MJ, Bubley G, Feng FY, ... ... Armstrong AJ, et al. Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2100169. PMID 34197212 DOI: 10.1200/JCO.21.00169 |
0.418 |
|
| 2021 |
Fong L, Morris MJ, Sartor O, Higano CS, Pagliaro L, Alva A, Appleman LJ, Tan W, Vaishampayan U, Porcu R, Tayama D, Kadel EE, Yuen KC, Datye A, Armstrong AJ, et al. A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34108181 DOI: 10.1158/1078-0432.CCR-21-0063 |
0.443 |
|
| 2021 |
Morris MJ, Mota JM, Lacuna K, Hilden P, Gleave M, Carducci MA, Saad F, Cohn ED, Filipenko J, Heller G, Shore N, Armstrong AJ, Scher HI. Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503). European Urology Oncology. PMID 34020931 DOI: 10.1016/j.euo.2021.04.008 |
0.34 |
|
| 2021 |
Iguchi T, Kimura G, Fukasawa S, Suzuki H, Uemura H, Nishimura K, Matsumoto H, Yokomizo A, Armstrong AJ, Rosbrook B, Sugg J, Baron B, Chen L, Kunieda F, Stenzl A. Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study. International Journal of Urology : Official Journal of the Japanese Urological Association. PMID 33955599 DOI: 10.1111/iju.14568 |
0.431 |
|
| 2021 |
George DJ, Halabi S, Heath EI, Sartor AO, Sonpavde GP, Das D, Bitting RL, Berry W, Healy P, Anand M, Winters C, Riggan C, Kephart J, Wilder R, Shobe K, ... ... Armstrong AJ, et al. A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer. Cancer. PMID 33951180 DOI: 10.1002/cncr.33589 |
0.432 |
|
| 2021 |
Scher HI, Armstrong AJ, Schonhoft JD, Gill A, Zhao JL, Barnett E, Carbone E, Lu J, Antonarakis ES, Luo J, Tagawa S, Dos Anjos CH, Yang Q, George D, Szmulewitz R, et al. Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer. European Journal of Cancer (Oxford, England : 1990). 150: 83-94. PMID 33894633 DOI: 10.1016/j.ejca.2021.02.042 |
0.443 |
|
| 2021 |
Brown LC, Halabi S, Schonhoft JD, Yang Q, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Barnett ES, Carbone EA, Zhao JL, Healy P, Anand M, Gill A, ... ... Armstrong AJ, et al. Circulating tumor cell chromosomal instability and neuroendocrine phenotype by immunomorphology and poor outcomes in men with mCRPC treated with abiraterone or enzalutamide. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33820782 DOI: 10.1158/1078-0432.CCR-20-3471 |
0.318 |
|
| 2021 |
Hawkey NM, Armstrong AJ. Liquid Biopsy: It's the Bloody Truth! Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33795259 DOI: 10.1158/1078-0432.CCR-21-0531 |
0.334 |
|
| 2021 |
Gupta S, Halabi S, Kemeny G, Anand M, Giannakakou P, Nanus DM, George DJ, Gregory SG, Armstrong AJ. Circulating tumor cell genomic evolution and hormone therapy outcomes in men with metastatic castration-resistant prostate cancer (mCRPC). Molecular Cancer Research : McR. PMID 33771885 DOI: 10.1158/1541-7786.MCR-20-0975 |
0.308 |
|
| 2021 |
Freedland SJ, Allen J, Jarman A, Oyekunle T, Armstrong AJ, Moul JW, Sandler HM, Posadas E, Levin D, Wiggins E, Howard LE, Wu Y, Lin PH. Correction: A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 27: 1823. PMID 33712498 DOI: 10.1158/1078-0432.CCR-21-0372 |
0.413 |
|
| 2021 |
Zhang T, Agarwal A, Almquist RG, Runyambo D, Park S, Bronson E, Boominathan R, Rao C, Anand M, Oyekunle T, Healy P, McNamara MA, Ware K, Somarelli JA, George DJ, ... Armstrong AJ, et al. Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer. Biomarker Research. 9: 14. PMID 33602330 DOI: 10.1186/s40364-021-00267-y |
0.354 |
|
| 2021 |
Armstrong AJ, Li X, Tucker M, Li S, Mu XJ, Eng KW, Sboner A, Rubin M, Gerstein M. Molecular medicine tumor board: whole-genome sequencing to inform on personalized medicine for a man with advanced prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 33568750 DOI: 10.1038/s41391-021-00324-5 |
0.353 |
|
| 2021 |
Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Bekelman JE, Cheng H, D'Amico AV, Davis BJ, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Horwitz EM, Ippolito JE, et al. NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. Journal of the National Comprehensive Cancer Network : Jnccn. 19: 134-143. PMID 33545689 DOI: 10.6004/jnccn.2021.0008 |
0.437 |
|
| 2021 |
Marshall CH, Fu W, Wang H, Park JC, DeWeese TL, Tran PT, Song DY, King S, Afful M, Hurrelbrink J, Manogue CE, Cotogno P, Moldawer NP, Barata P, Drake CG, ... ... Armstrong AJ, et al. Randomized phase II trial of sipuleucel-T with or without radium-223 in men with bone-metastatic castration-resistant prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33451978 DOI: 10.1158/1078-0432.CCR-20-4476 |
0.415 |
|
| 2021 |
Tombal B, Stenzl A, Cella D, Loriot Y, Armstrong AJ, Fizazi K, Beer T, Sternberg CN, Hussain M, Ivanescu C, Ganguli A, Ramaswamy K, Saad F. The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials Cancers. 13: 5872. DOI: 10.3390/cancers13235872 |
0.41 |
|
| 2021 |
Zhang T, Koontz BF, Tagawa ST, Nagar H, Bitting RL, Frizzell B, Nordquist LT, Rasmussen J, Wilder R, Anand M, Winters C, Riggan C, Fernandez E, Healy P, Oyekunle T, ... ... Armstrong AJ, et al. Interim analysis of STARTAR: A phase II salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP). Journal of Clinical Oncology. 39: 90-90. DOI: 10.1200/JCO.2021.39.6_SUPPL.90 |
0.409 |
|
| 2021 |
Brown LC, Halabi S, Humeniuk MS, Wu Y, Oyekunle T, Huang J, Anand M, Davies C, Zhang T, Harrison MR, George DJ, Armstrong AJ. Efficacy of the PD-L1 inhibitor avelumab in neuroendocrine or aggressive variant prostate cancer: Results from a phase II, single-arm study. Journal of Clinical Oncology. 39: 89-89. DOI: 10.1200/JCO.2021.39.6_SUPPL.89 |
0.364 |
|
| 2021 |
Scher HI, Armstrong AJ, Schonhoft JD, Gill A, Zhao J, Barnett E, Carbone E, Lu J, Antonarakis ES, Luo J, Tagawa ST, Yang Q, George DJ, Szmulewitz RZ, Danila DC, et al. Development and validation of circulating tumor cell (Epic Sciences) enumeration as a prognostic biomarker in men with metastatic castration-resistant prostate cancer. Journal of Clinical Oncology. 39: 157-157. DOI: 10.1200/JCO.2021.39.6_SUPPL.157 |
0.382 |
|
| 2021 |
Fizazi K, González Mella P, Castellano D, Minatta JN, Rezazadeh A, Shaffer DR, Vazquez Limon JC, Sánchez López HM, Armstrong AJ, Horvath L, Dzik C, Amin NP, Li J, Unsal-Kacmaz K, Retz M, et al. CheckMate 9KD Arm B final analysis: Efficacy and safety of nivolumab plus docetaxel for chemotherapy-naïve metastatic castration-resistant prostate cancer. Journal of Clinical Oncology. 39: 12-12. DOI: 10.1200/JCO.2021.39.6_SUPPL.12 |
0.365 |
|
| 2021 |
Shore ND, Iguchi T, Villers A, Alcaraz A, Gomez-Veiga F, Stenzl A, Azad AA, Alekseev B, Petrylak DP, Szmulewitz RZ, Holzbeierlein J, Rosbrook B, Zohren F, Haas GP, Gourgioti G, ... ... Armstrong AJ, et al. PD34-07 ENZALUTAMIDE IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER PATIENTS WHO RECEIVED PRIOR ANTIANDROGEN THERAPY: POST HOC ANALYSIS OF ARCHES Journal of Urology. 206. DOI: 10.1097/JU.0000000000002038.07 |
0.363 |
|
| 2021 |
Autio KA, Antonarakis ES, Mayer TM, Shevrin DH, Stein MN, Vaishampayan UN, Morris MJ, Slovin SF, Heath EI, Tagawa ST, Rathkopf DE, Milowsky MI, Harrison MR, Beer TM, Balar AV, ... Armstrong AJ, et al. Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy European Urology Open Science. 34: 70-78. DOI: 10.1016/j.euros.2021.09.015 |
0.423 |
|
| 2020 |
Armstrong AJ, Shore ND, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Gomez-Veiga F, Rosbrook B, Lee HJ, Haas GP, Stenzl A. Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses. The Journal of Urology. 101097JU000000000000. PMID 33356529 DOI: 10.1097/JU.0000000000001568 |
0.448 |
|
| 2020 |
Koontz BF, Hoffman KE, Halabi S, Healy P, Anand M, George DJ, Harrison MR, Zhang T, Berry WR, Corn PG, Lee WR, Armstrong AJ. Combination of Radiotherapy and Short-Term Androgen Blockade with Abiraterone Acetate plus Prednisone for Men with High and Intermediate Risk Localized Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics. PMID 33259932 DOI: 10.1016/j.ijrobp.2020.11.059 |
0.366 |
|
| 2020 |
Armstrong AJ, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Healy P, Anand M, Berry WR, Zhang T, Harrison MR, Lu C, Chen Y, Galletti G, Schonhoft JD, et al. Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer. Jco Precision Oncology. 4. PMID 33154984 DOI: 10.1200/PO.20.00200 |
0.45 |
|
| 2020 |
Powers E, Karachaliou GS, Kao C, Harrison MR, Hoimes CJ, George DJ, Armstrong AJ, Zhang T. Novel therapies are changing treatment paradigms in metastatic prostate cancer. Journal of Hematology & Oncology. 13: 144. PMID 33115529 DOI: 10.1186/s13045-020-00978-z |
0.446 |
|
| 2020 |
Wu M, Huang PH, Zhang R, Mao Z, Chen C, Kemeny G, Li P, Lee AV, Gyanchandani R, Armstrong AJ, Dao M, Suresh S, Huang TJ. Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation. Small (Weinheim An Der Bergstrasse, Germany). 16: e2004438. PMID 32851785 DOI: 10.1002/Smll.202004438 |
0.325 |
|
| 2020 |
Schweizer MT, Ha G, Gulati R, Brown LC, McKay RR, Dorff T, Hoge ACH, Reichel J, Vats P, Kilari D, Patel V, Oh WK, Chinnaiyan A, Pritchard CC, Armstrong AJ, et al. -Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade. Jco Precision Oncology. 4: 382-392. PMID 32671317 DOI: 10.1200/po.19.00383 |
0.337 |
|
| 2020 |
Armstrong AJ, Lin P, Tombal B, Saad F, Higano CS, Joshua AM, Parli T, Rosbrook B, van Os S, Beer TM. Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial. European Urology. PMID 32527692 DOI: 10.1016/J.Eururo.2020.04.061 |
0.453 |
|
| 2020 |
Stenzl A, Dunshee C, De Giorgi U, Alekseev B, Iguchi T, Szmulewitz RZ, Flaig TW, Tombal B, Morlock R, Ivanescu C, Ramaswamy K, Saad F, Armstrong AJ. Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study. European Urology. PMID 32336645 DOI: 10.1016/J.Eururo.2020.03.019 |
0.422 |
|
| 2020 |
Lu C, Brown LC, Antonarakis ES, Armstrong AJ, Luo J. Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations. Prostate Cancer and Prostatic Diseases. PMID 32139878 DOI: 10.1038/s41391-020-0217-3 |
0.379 |
|
| 2020 |
Sartor O, Armstrong AJ, Ahaghotu C, McLeod DG, Cooperberg MR, Penson DF, Kantoff PW, Vogelzang NJ, Hussain A, Pieczonka CM, Shore ND, Quinn DI, Small EJ, Heath EI, Tutrone RF, et al. Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. Prostate Cancer and Prostatic Diseases. PMID 32111923 DOI: 10.1038/S41391-020-0213-7 |
0.394 |
|
| 2020 |
Freedland SJ, Allen J, Jarman A, Oyekunle T, Armstrong AJ, Moul JW, Sandler H, Posadas EM, Levin D, Wiggins E, Howard LE, Wu Y, Lin PH. A Randomized Controlled Trial of a 6-month low carbohydrate intervention on disease progression in men with recurrent prostate cancer: Carbohydrate and Prostate Study 2 (CAPS2). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32108029 DOI: 10.1158/1078-0432.CCR-19-3873 |
0.37 |
|
| 2020 |
Brown LC, Lu C, Antonarakis ES, Luo J, Armstrong AJ. Androgen receptor variant-driven prostate cancer II: advances in clinical investigation. Prostate Cancer and Prostatic Diseases. PMID 32094489 DOI: 10.1038/s41391-020-0215-5 |
0.341 |
|
| 2020 |
Bitting RL, Healy P, George DJ, Anand M, Kim S, Mayer T, Winters C, Riggan C, Rasmussen J, Wilder R, Stein M, Frizzell B, Harrison MR, Zhang T, Lee WR, ... ... Armstrong AJ, et al. Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial. European Urology Oncology. PMID 32063492 DOI: 10.1016/J.Euo.2020.01.005 |
0.436 |
|
| 2020 |
Kinsey EN, Zhang T, Armstrong AJ. Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape. Cancer Journal (Sudbury, Mass.). 26: 64-75. PMID 31977388 DOI: 10.1097/PPO.0000000000000418 |
0.405 |
|
| 2020 |
Zhang T, Kephart J, Bronson E, Anand M, Daly C, Spasojevic I, Berg H, James OG, Healy P, Halabi S, Harrison MR, Armstrong AJ, George DJ. Disulfiram (DSF) pharmacokinetics (PK) and copper PET imaging in a phase Ib study of intravenous (IV) copper loading with oral DSF for patients with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 38: 96-96. DOI: 10.1200/Jco.2020.38.6_Suppl.96 |
0.333 |
|
| 2020 |
Gupta S, Halabi S, Kemeny G, Anand M, Nanus DM, Giannakakou P, George DJ, Gregory S, Armstrong AJ. Circulating tumor cell (CTC) genomic signatures of hormone therapy resistance in men with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 38: 147-147. DOI: 10.1200/Jco.2020.38.6_Suppl.147 |
0.399 |
|
| 2020 |
Marshall CH, Park JC, DeWeese TL, King S, Afful M, Hurrelbrink J, Manogue C, Cotogno P, Moldawer NP, Barata PC, Drake CG, Posadas EM, Armstrong AJ, Sartor AO, Antonarakis ES. Randomized phase II study of sipuleucel-T (SipT) with or without radium-223 (Ra223) in men with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 38: 130-130. DOI: 10.1200/Jco.2020.38.6_Suppl.130 |
0.355 |
|
| 2020 |
Yu EY, Pieczonka CM, Briganti A, Murphy DG, Lebret T, Luz M, Suzuki H, Thiery-Vuillemin A, Ortiz JA, Guan R, Armstrong AJ. DAROL: DARolutamide ObservationaL study patients in nonmetastatic castration-resistant prostate cancer (nmCRPC) patients. Journal of Clinical Oncology. 38: TPS5593-TPS5593. DOI: 10.1200/jco.2020.38.15_suppl.tps5593 |
0.408 |
|
| 2020 |
Kelly WK, Danila DC, Edenfield WJ, Aggarwal RR, Petrylak DP, Sartor AO, Sumey CJ, Dorff TB, Yu EY, Adra N, Waterhouse DM, Armstrong AJ, Horvath L, Pook DW, Appleman LJ, et al. Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 38: TPS5589-TPS5589. DOI: 10.1200/jco.2020.38.15_suppl.tps5589 |
0.38 |
|
| 2020 |
Marshall CH, Park JC, Fu W, Wang H, DeWeese TL, King S, Afful M, Hurrelbrink J, Manogue C, Cotogno P, Moldawer NP, Barata PC, Drake CG, Posadas EM, Armstrong AJ, et al. Results of the randomized phase II study of sipuleucel-T (Sip-T) +/- Radium-223 (Ra-223) in men with bone-metastatic castration resistant prostate cancer. Journal of Clinical Oncology. 38: 5563-5563. DOI: 10.1200/Jco.2020.38.15_Suppl.5563 |
0.306 |
|
| 2020 |
Shore ND, Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Gomez-Veiga F, Rosbrook B, Lee H, Haas GP, Stenzl A. Efficacy of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) by pattern of metastatic spread: ARCHES post hoc analyses. Journal of Clinical Oncology. 38: 5547-5547. DOI: 10.1200/jco.2020.38.15_suppl.5547 |
0.347 |
|
| 2020 |
Sartor O, Armstrong AJ, Ahaghotu C, McLeod DG, Cooperberg MR, Penson DF, Kantoff PW, Vogelzang NJ, Hussain A, Pieczonka CM, Shore ND, Quinn DI, Heath EI, Tutrone RF, Schellhammer PF, et al. Abstract D084: Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC)—final PROCEED analysis Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp19-D084 |
0.407 |
|
| 2020 |
Patierno BM, Glover W, Foo W, Somarelli JA, Ware KE, Xu L, Li Y, Chen X, George DJ, Kittles RA, Armstrong AJ, McCall SJ, Huang J, Freedman JA, Patierno SR, et al. Abstract A114: Characterization of a metastatic prostate cancer xenograft derived from a patient of African ancestry Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp18-A114 |
0.369 |
|
| 2020 |
Shore* ND, Crawford ED, Szmulewitz RZ, Petrylak D, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Gomez-Veiga F, Rosbrook B, Baron B, Haas GP, Stenzl A, ... Armstrong AJ, et al. PD10-10 IMPACT OF BASELINE DISEASE VOLUME AND PRIOR DOCETAXEL THERAPY ON PROSTATE-SPECIFIC ANTIGEN-RELATED OUTCOMES IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER TREATED WITH ENZALUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY Journal of Urology. 203. DOI: 10.1097/JU.0000000000000844.010 |
0.398 |
|
| 2020 |
Saad F, Armstrong A, Ivanescu C, Bhadauria H, Ramaswamy K, Morlock R, Tombal B. Impact of Enzalutamide (ENZA) on Patient-Reported Outcomes (PROs) in metastatic Hormone-Sensitive Prostate Cancer (mHSPC) patients with no/low urinary symptoms at baseline: Results from the ARCHES study European Urology Open Science. 19: e867-e868. DOI: 10.1016/s2666-1683(20)33161-x |
0.349 |
|
| 2020 |
Stenzl A, Szmulewitz R, Petrylak D, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore N, Gomez-Veiga F, Rosbrook B, Baron B, Haas G, Armstrong A. ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC) by prior local and systemic treatment European Urology Open Science. 19: e865-e866. DOI: 10.1016/s2666-1683(20)33160-8 |
0.4 |
|
| 2020 |
Tombal B, Freedland S, Armstrong A, Beer T, Stenzl A, Sternberg C, Hussain M, Ganguli A, Ramaswamy K, Bhadauria H, Ivanescu C, Turnbull J, Holmstrom S, Saad F. 665P Impact of enzalutamide on patient-reported fatigue in hormone-sensitive prostate cancer (HSPC) or castration-resistant prostate cancer (CRPC) Annals of Oncology. 31: S536-S537. DOI: 10.1016/j.annonc.2020.08.924 |
0.433 |
|
| 2020 |
Alcaraz A, Szmulewitz R, Shore N, Crawford E, Petrylak D, Holzbeierlein J, Villers A, Azad A, Alekseev B, Iguchi T, Gomez-Veiga F, Rosbrook B, Sugg J, Haas G, Stenzl A, ... Armstrong A, et al. 635P ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of efficacy by baseline prostate-specific antigen (PSA) levels Annals of Oncology. 31: S523-S524. DOI: 10.1016/j.annonc.2020.08.894 |
0.424 |
|
| 2019 |
Armstrong AJ, Al-Adhami M, Lin P, Parli T, Sugg J, Steinberg J, Tombal B, Sternberg CN, de Bono J, Scher HI, Beer TM. Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials. Jama Oncology. PMID 31830211 DOI: 10.1001/jamaoncol.2019.4636 |
0.402 |
|
| 2019 |
Eggener SE, Rumble RB, Armstrong AJ, Morgan TM, Crispino T, Cornford P, van der Kwast T, Grignon DJ, Rai AJ, Agarwal N, Klein EA, Den RB, Beltran H. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902768. PMID 31829902 DOI: 10.1200/JCO.19.02768 |
0.367 |
|
| 2019 |
Li Y, He Y, Butler W, Xu L, Chang Y, Lei K, Zhang H, Zhou Y, Gao AC, Zhang Q, Taylor DG, Cheng D, Farber-Katz S, Karam R, Landrith T, ... ... Armstrong AJ, et al. Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer. Science Translational Medicine. 11. PMID 31801883 DOI: 10.1126/Scitranslmed.Aax0428 |
0.353 |
|
| 2019 |
George DJ, Halabi S, Healy P, Jonasch D, Anand M, Rasmussen J, Wood SY, Spritzer C, Madden JF, Armstrong AJ. Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer. Urologic Oncology. PMID 31522863 DOI: 10.1016/j.urolonc.2019.08.015 |
0.397 |
|
| 2019 |
Yuan F, Hankey W, Wu D, Wang H, Somarelli J, Armstrong AJ, Huang J, Chen Z, Wang Q. Molecular determinants for enzalutamide-induced transcription in prostate cancer. Nucleic Acids Research. PMID 31501863 DOI: 10.1093/Nar/Gkz790 |
0.358 |
|
| 2019 |
George DJ, Halabi S, Healy P, Barak I, Winters C, Anand M, Wilder R, Klein M, Martinez E, Nixon AB, Harrison MR, Szmulewitz R, Armstrong AJ. Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. The Prostate. PMID 31497882 DOI: 10.1002/Pros.23899 |
0.394 |
|
| 2019 |
Higano CS, Armstrong AJ, Sartor AO, Vogelzang NJ, Kantoff PW, McLeod DG, Pieczonka CM, Penson DF, Shore ND, Vacirca J, Concepcion RS, Tutrone RF, Nordquist LT, Quinn DI, Kassabian V, et al. Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer. Cancer. PMID 31483485 DOI: 10.1002/cncr.32445 |
0.428 |
|
| 2019 |
Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore ND, Rosbrook B, Sugg J, Baron B, Chen L, Stenzl A. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900799. PMID 31329516 DOI: 10.1200/JCO.19.00799 |
0.463 |
|
| 2019 |
Zhu J, Tucker M, Marin D, Gupta RT, Healy P, Humeniuk M, Jarvis C, Zhang T, McNamara M, George DJ, Wu Y, Lisi S, Armstrong AJ. Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer. Urologic Oncology. PMID 31327751 DOI: 10.1016/j.urolonc.2019.06.015 |
0.454 |
|
| 2019 |
Tucker MD, Zhu J, Marin D, Gupta RT, Gupta S, Berry WR, Ramalingam S, Zhang T, Harrison M, Wu Y, Healy P, Lisi S, George DJ, Armstrong AJ. Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer. Cancer Medicine. PMID 31270961 DOI: 10.1002/Cam4.2375 |
0.461 |
|
| 2019 |
Armstrong AJ, Gupta S, Healy P, Kemeny G, Leith B, Zalutsky MR, Spritzer C, Davies C, Rothwell C, Ware K, Somarelli JA, Wood K, Ribar T, Giannakakou P, Zhang J, et al. Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer. Plos One. 14: e0216934. PMID 31136607 DOI: 10.1371/Journal.Pone.0216934 |
0.403 |
|
| 2019 |
Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel MR, et al. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 17: 479-505. PMID 31085757 DOI: 10.6004/Jnccn.2019.0023 |
0.432 |
|
| 2019 |
McNamara MA, Oyekunle T, Chin BB, Oldan J, Anand A, Ritz M, Shantzer L, Anand M, Armstrong AJ, George DJ. Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer. The Prostate. PMID 31045266 DOI: 10.1002/pros.23822 |
0.395 |
|
| 2019 |
Mota JM, Armstrong AJ, Larson SM, Fox JJ, Morris MJ. Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials. Prostate Cancer and Prostatic Diseases. PMID 31036925 DOI: 10.1038/s41391-019-0151-4 |
0.373 |
|
| 2019 |
Holl EK, McNamara MA, Healy P, Anand M, Concepcion RS, Breland CD, Dumbudze I, Tutrone R, Shore N, Armstrong AJ, Harrison M, Wallace JA, Wu Y, George DJ. Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients. Prostate Cancer and Prostatic Diseases. PMID 30980027 DOI: 10.1038/S41391-019-0144-3 |
0.412 |
|
| 2019 |
Armstrong AJ, Halabi S, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Healy P, Anand M, Rothwell CJ, Rasmussen J, Thornburg B, Berry WR, Wilder RS, Lu C, et al. Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1801731. PMID 30865549 DOI: 10.1200/Jco.18.01731 |
0.325 |
|
| 2019 |
Freedland SJ, Howard L, Allen J, Smith J, Stout J, Aronson W, Inman BA, Armstrong AJ, George D, Westman E, Lin PH. A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial. Prostate Cancer and Prostatic Diseases. PMID 30664736 DOI: 10.1038/s41391-019-0126-5 |
0.335 |
|
| 2019 |
Sonpavde G, Agarwal N, Pond GR, Nagy RJ, Nussenzveig RH, Hahn AW, Sartor O, Gourdin TS, Nandagopal L, Ledet EM, Naik G, Armstrong AJ, Wang J, Bilen MA, Gupta S, et al. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. Cancer. PMID 30620391 DOI: 10.1002/Cncr.31959 |
0.415 |
|
| 2019 |
Armstrong AJ, Nordle O, Morris M. Assessing the Prognostic Value of the Automated Bone Scan Index for Prostate Cancer-Reply. Jama Oncology. 5: 270-271. PMID 30543364 DOI: 10.1001/jamaoncol.2018.5874 |
0.349 |
|
| 2019 |
Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Ye D, Mateo J, Goessl CD, Kang J, Liu S, Saad F. PROPEL: A randomized, phase III trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.7_Suppl.Tps340 |
0.316 |
|
| 2019 |
Chowdhury S, Mateo J, Gross M, Armstrong AJ, Cruz-Correa M, Piulats JM, Blay J, Rivas D, Quintero L, Castro H, Nkobena A, Raponi M, Pelham R, Landers MA, Montgomery RB. A phase II trial in progress: Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer and a circulating tumor cell homologous recombination deficiency (HRD) phenotype or BRCA defects. Journal of Clinical Oncology. 37: TPS328-TPS328. DOI: 10.1200/jco.2019.37.7_suppl.tps328 |
0.405 |
|
| 2019 |
Armstrong AJ, Szmulewitz RZ, Petrylak DP, Villers A, Azad A, Alcaraz A, Alekseev BY, Iguchi T, Shore ND, Rosbrook B, Sugg J, Baron B, Chen LF, Stenzl A. Phase III study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial. Journal of Clinical Oncology. 37: 687-687. DOI: 10.1200/JCO.2019.37.7_SUPPL.687 |
0.447 |
|
| 2019 |
Armstrong AJ, Bitting RL, Healy P, George DJ, Kim S, Mayer TM, Winters C, Riggan C, Rasmussen J, Wilder R, Anand M, Stein MN, Frizzell B, Harrison MR, Zhang T, et al. Phase II trial enzalutamide and androgen deprivation therapy (ADT) with salvage radiation in men with high-risk PSA recurrent prostate cancer (PC): The STREAM trial. Journal of Clinical Oncology. 37: 29-29. DOI: 10.1200/Jco.2019.37.7_Suppl.29 |
0.401 |
|
| 2019 |
Tombal BF, Armstrong AJ, Barrus JK, Beer TM, Chowdhury S, Evans CP, Heidenreich A, Higano CS, Kamba T, Lin P, Nikolayeva N, Sugg J, Steinberg JL, Taplin ME, Saad F. Adverse events of special interest assessed by review of safety data in enzalutamide castration-resistant prostate cancer (CRPC) trials. Journal of Clinical Oncology. 37: 237-237. DOI: 10.1200/Jco.2019.37.7_Suppl.237 |
0.395 |
|
| 2019 |
Armstrong AJ, Olsson CA, Schnadig ID, Concepcion RS, Vacirca JL, Tutrone RF, Dakhil SR, Chang NN, Tang H, Brown B, Vogelzang NJ. Real-world PROCEED registry data: Sipuleucel-T in elderly men with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 37: 177-177. DOI: 10.1200/JCO.2019.37.7_SUPPL.177 |
0.334 |
|
| 2019 |
Vogelzang NJ, Kantoff PW, Scholz MC, Vacirca JL, Dakhil SR, Goel S, Harmon M, Tang H, Brown B, Armstrong AJ. Experience with sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) with visceral spread from PROCEED. Journal of Clinical Oncology. 37: 174-174. DOI: 10.1200/JCO.2019.37.7_SUPPL.174 |
0.327 |
|
| 2019 |
Tucker MD, Zhu J, Berry WR, Ramalingam S, Zhang T, Harrison MR, Wu Y, Healy P, George DJ, Armstrong AJ. Pembrolizumab in men with heavily treated metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 37: 172-172. DOI: 10.1200/Jco.2019.37.7_Suppl.172 |
0.375 |
|
| 2019 |
Zhang T, Koontz BF, Tagawa ST, Nagar H, Bitting RL, Frizzell B, Rasmussen J, Wilder R, Anand M, Winters C, Riggan C, Lee A, Healy P, Wu Y, McNamara MA, ... ... Armstrong AJ, et al. A phase II Salvage Trial of AR Inhibition with ADT and Apalutamide with Radiation therapy followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (STARTAR). Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.Tps5097 |
0.373 |
|
| 2019 |
Chowdhury S, Mateo J, Gross M, Armstrong AJ, Cruz-Correa M, Piulats JM, Blay J, Li M, Rivas D, Quintero L, Castro H, Nkobena A, Raponi M, Pelham R, Landers M, et al. Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) and a circulating tumor cell (CTC) homologous recombination deficiency (HRD) phenotype or BRCA defects: A trial in progress. Journal of Clinical Oncology. 37: TPS5086-TPS5086. DOI: 10.1200/JCO.2019.37.15_SUPPL.TPS5086 |
0.358 |
|
| 2019 |
Autio KA, Antonarakis ES, Baser R, Stein MN, Shevrin DH, Vaishampayan UN, Mayer TM, Morris MJ, Slovin SF, Heath EI, Tagawa ST, Rathkopf DE, Milowsky MI, Harrison MR, Beer TM, ... ... Armstrong AJ, et al. Evaluation of the patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) with abiraterone acetate plus prednisone (AAP), degarelix (D), or the combination in men with biochemically recurrent prostate cancer (BCRPC). Journal of Clinical Oncology. 37: 5080-5080. DOI: 10.1200/Jco.2019.37.15_Suppl.5080 |
0.336 |
|
| 2019 |
Mara A, Zhu J, Wu Y, Callis T, Yang S, Esplin ED, Nussbaum RL, Zhang T, McNamara MA, Harrison MR, George DJ, Cooney KA, Armstrong AJ. Prevalence of pathogenic germline variants in DNA repair by race, age, and ethnicity in men with prostate cancer. Journal of Clinical Oncology. 37: 5062-5062. DOI: 10.1200/Jco.2019.37.15_Suppl.5062 |
0.361 |
|
| 2019 |
Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein JM, Villers A, Azad A, Alcaraz A, Alekseev BY, Iguchi T, Shore ND, Rosbrook B, Baron B, Chen LF, Stenzl A. ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC). Journal of Clinical Oncology. 37: 5048-5048. DOI: 10.1200/JCO.2019.37.15_SUPPL.5048 |
0.418 |
|
| 2019 |
Stenzl A, Dunshee C, Giorgi UD, Alekseev B, Iguchi T, Szmulewitz RZ, Flaig TW, Tombal BF, Morlock R, Ivanescu C, Ramaswamy K, Saad F, Armstrong AJ. Health-related quality of life (HRQoL) and pain progression with enzalutamide (ENZ) in metastatic hormone-sensitive prostate cancer (mHSPC) from the ARCHES study. Journal of Clinical Oncology. 37: 5044-5044. DOI: 10.1200/Jco.2019.37.15_Suppl.5044 |
0.358 |
|
| 2019 |
Sartor AO, Armstrong AJ, Ahaghotu C, McLeod DG, Cooperberg MR, Penson DF, Kantoff PW, Vogelzang NJ, Hussain A, Pieczonka CM, Shore ND, Quinn DI, Small EJ, Heath EI, Tutrone RF, et al. Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC): Final PROCEED analysis. Journal of Clinical Oncology. 37: 5035-5035. DOI: 10.1200/Jco.2019.37.15_Suppl.5035 |
0.445 |
|
| 2019 |
Morris MJ, Heller G, Bryce AH, Armstrong AJ, Beltran H, Hahn OM, McGary EC, Mehan PT, Goldkorn A, Roth BJ, Xiao H, Watt C, Hillman DW, Taplin M, Ryan CJ, et al. Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 37: 5008-5008. DOI: 10.1200/Jco.2019.37.15_Suppl.5008 |
0.41 |
|
| 2019 |
Stenzl* A, Szmulewitz RZ, Petrylak D, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore ND, Rosbrook B, Baron B, Kunieda F, Morlock R, Ramaswamy K, ... Armstrong AJ, et al. LBA-10 ARCHES – EFFICACY OF ANDROGEN DEPRIVATION THERAPY WITH ENZALUTAMIDE OR PLACEBO IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER: PROSTATE-SPECIFIC ANTIGEN RESULTS Journal of Urology. 201. DOI: 10.1097/01.JU.0000557502.92839.76 |
0.427 |
|
| 2019 |
Karsh* LI, Armstrong AJ, Pieczonka C, Dakhil S, Vacirca J, Vogelzang NJ, Concepcion RS, Bailen J, Mantz C, Tutrone RF, Chang NN, Tang H, Brown B, Scholz MC. PD25-06 CHARACTERIZATION OF LONG-TERM SURVIVORS FROM PROCEED, A REGISTRY OF SIPULEUCEL-T IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) Journal of Urology. 201. DOI: 10.1097/01.JU.0000555911.55061.66 |
0.346 |
|
| 2019 |
Fizazi K, Mella PG, Castellano D, Minatta JN, Kalebasty AR, Shaffer D, Limon JCV, Armstrong AJ, Lopez HMS, Sharkey B, Saci A, Li J, Wang X, Ciprotti M, Sathyanarayana P, et al. Efficacy and safety of nivolumab in combination with docetaxel in men with metastatic castration-resistant prostate cancer in CheckMate 9KD Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz394.045 |
0.43 |
|
| 2019 |
Tran B, Kouros-Mehr H, Fermin A, Horvath L, Roncolato F, Rettig M, Dorff T, Tagawa S, Subudhi S, Antonarakis E, Armstrong A, Petrylak D, Fizazi K, Salvati M, Scher H. A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) Annals of Oncology. 30: v353. DOI: 10.1093/Annonc/Mdz248.052 |
0.404 |
|
| 2019 |
Stenzl A, Szmulewitz R, Petrylak D, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore N, Rosbrook B, Baron B, Haas G, Morlock R, Ramaswamy K, ... Armstrong A, et al. ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups Annals of Oncology. 30: v332-v333. DOI: 10.1093/annonc/mdz248.010 |
0.387 |
|
| 2019 |
Basso U, Galetti TP, Armstrong A, Szmulewitz R, Petrylak D, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore N, Rosbrook B, Sugg J, Baron B, Chen L, et al. Phase 3 study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (MHSPC): The ARCHES trial European Urology Supplements. 18: e3258. DOI: 10.1016/s1569-9056(19)33650-4 |
0.419 |
|
| 2019 |
Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Ye D, Mateo J, Goessl C, Kang J, Liu S, Saad F. PROPEL: A randomized phase III trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) European Urology Supplements. 18. DOI: 10.1016/S1569-9056(19)31321-1 |
0.392 |
|
| 2019 |
Armstrong A, Tombal B, Saad F, Parli T, Phung D, Beer TM. Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Long-term overall survival and safety analyses of the phase 3 PREVAIL study European Urology Supplements. 18. DOI: 10.1016/S1569-9056(19)30874-7 |
0.414 |
|
| 2018 |
Harrison MR, Davis PG, Khouri MG, Gupta RT, Armstrong AJ, McNamara MA, Zhang T, Anand M, Onyenwoke K, Hood H, Edwardson S, Craig D, Wu Y, Healy P, Coyne B, et al. EXTEND: Safety and efficacy of exercise training in men receiving enzalutamide (ENZ) in combination with conventional androgen deprivation therapy (ADT) for hormone naïve prostate cancer (HSPC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii623-viii624. PMID 32137677 DOI: 10.1093/annonc/mdy300.064 |
0.355 |
|
| 2018 |
Armstrong AJ, Lin P, Higano CS, Iversen P, Sternberg CN, Tombal B, Phung, Parli T, Krivoshik A, Beer TM. Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial. European Urology Oncology. PMID 31274110 DOI: 10.1016/j.euo.2018.11.005 |
0.444 |
|
| 2018 |
Sumanasuriya S, Omlin A, Armstrong A, Attard G, Chi KN, Bevan CL, Shibakawa A, IJzerman MJ, De Laere B, Lolkema M, Lorente D, Luo J, Mehra N, Olmos D, Scher H, et al. Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer. European Urology Oncology. 1: 151-159. PMID 31100240 DOI: 10.1016/j.euo.2018.02.009 |
0.391 |
|
| 2018 |
Zhang T, Armstrong AJ, George DJ, Huang J. The promise of immunotherapy in genitourinary malignancies. Precision Clinical Medicine. 1: 97-101. PMID 30687563 DOI: 10.1093/pcmedi/pby018 |
0.348 |
|
| 2018 |
Armstrong AJ. Updates in advanced prostate cancer 2018. Prostate Cancer and Prostatic Diseases. PMID 30279577 DOI: 10.1038/s41391-018-0100-7 |
0.436 |
|
| 2018 |
Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J, Mosquera JM, Sailer V, Bareja R, Romanel A, Gumpeni N, et al. A phase II trial of the aurora kinase A inhibitor alisertib for patients with castration resistant and neuroendocrine prostate cancer: efficacy and biomarkers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30232224 DOI: 10.1158/1078-0432.CCR-18-1912 |
0.426 |
|
| 2018 |
Zhang T, George DJ, Armstrong AJ. Precision medicine approaches when prostate cancer Akts up. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30206162 DOI: 10.1158/1078-0432.CCR-18-2491 |
0.449 |
|
| 2018 |
Armstrong AJ, Lin P, Higano CS, Sternberg CN, Sonpavde G, Tombal B, Templeton AJ, Fizazi K, Phung D, Wong EK, Krivoshik A, Beer TM. Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30202945 DOI: 10.1093/annonc/mdy406 |
0.427 |
|
| 2018 |
Wu M, Huang PH, Zhang R, Mao Z, Chen C, Kemeny G, Li P, Lee AV, Gyanchandani R, Armstrong AJ, Dao M, Suresh S, Huang TJ. Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation. Small (Weinheim An Der Bergstrasse, Germany). e1801131. PMID 29968402 DOI: 10.1002/smll.201801131 |
0.325 |
|
| 2018 |
Fantony JJ, Howard LE, Csizmadi I, Armstrong AJ, Lark AL, Galet C, Aronson WJ, Freedland SJ. Is Ki67 prognostic for aggressive prostate cancer? A multicenter real-world study. Biomarkers in Medicine. PMID 29902938 DOI: 10.2217/bmm-2017-0322 |
0.38 |
|
| 2018 |
Brown LC, Sonpavde G, Armstrong AJ. Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer? Prostate Cancer and Prostatic Diseases. PMID 29858595 DOI: 10.1038/s41391-018-0049-6 |
0.417 |
|
| 2018 |
Rathkopf DE, Beer TM, Loriot Y, Higano CS, Armstrong AJ, Sternberg CN, de Bono JS, Tombal B, Parli T, Bhattacharya S, Phung, Krivoshik A, Scher HI, Morris MJ. Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial. Jama Oncology. PMID 29522174 DOI: 10.1001/jamaoncol.2017.5808 |
0.419 |
|
| 2018 |
McNamara M, Sweeney C, Antonarakis ES, Armstrong AJ. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation. Prostate Cancer and Prostatic Diseases. 21: 306-318. PMID 29263421 DOI: 10.1038/s41391-017-0014-9 |
0.407 |
|
| 2018 |
Sumanasuriya S, Omlin AG, Armstrong AJ, Attard G, Chi KN, Bevan CL, Waugh DJ, Ijzerman MJ, De Laere B, Lolkema MP, Lorente D, Luo J, Mehra N, Olmos D, Scher HI, et al. Consensus statement on circulating biomarkers for advanced prostate cancer. Journal of Clinical Oncology. 36: 299-299. DOI: 10.1200/jco.2018.36.6_suppl.299 |
0.319 |
|
| 2018 |
Armstrong AJ, Gupta S, Healy P, Kemeny G, Leith LB, Zalutsky M, Spritzer C, Davies C, Ware K, Somarelli J, Wood K, Glover W, Hsu SD, Gerber D, Rothwell C, et al. Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223. Journal of Clinical Oncology. 36: 160-160. DOI: 10.1200/Jco.2018.36.6_Suppl.160 |
0.312 |
|
| 2018 |
Koontz BF, Hoffman KE, Healy P, George DJ, Harrison MR, Zhang T, Lee WR, Berry WR, Pugh TJ, Corn PG, Bratt L, Shobe K, Thornburg B, Allen DM, Brummer K, ... ... Armstrong AJ, et al. Phase II trial of 6 months ADT/abiraterone acetate plus prednisone (AAP) and definitive radiotherapy (AbiRT) for men with intermediate to high risk localized prostate cancer. Journal of Clinical Oncology. 36: 11-11. DOI: 10.1200/Jco.2018.36.6_Suppl.11 |
0.424 |
|
| 2018 |
Higano CS, Armstrong AJ, Sartor AO, Vogelzang NJ, Kantoff PW, McLeod DG, Pieczonka CM, Penson DF, Shore ND, Vacirca JL, Concepcion RS, Tutrone RF, Nordquist LT, Quinn DI, Kassabian V, et al. Cerebrovascular event (CVE) outcome and overall survival (OS) in patients (pts) treated with sipuleucel-T (sip-T) for metastatic castration-resistant prostate cancer (mCRPC): results from the PROCEED registry. Journal of Clinical Oncology. 36: e17018-e17018. DOI: 10.1200/JCO.2018.36.15_SUPPL.E17018 |
0.37 |
|
| 2018 |
Shantzer L, Ritz M, Chin BB, Oldan J, Anand A, Oyekunle T, Anand M, Armstrong AJ, George DJ, McNamara MA. Patterns of bone scan and pain response following treatment with Ra-223 in metastatic castrate resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 36: e17011-e17011. DOI: 10.1200/JCO.2018.36.15_SUPPL.E17011 |
0.32 |
|
| 2018 |
Zhang T, Austin RG, Park SE, Runyambo D, Boominathan R, Rao C, Bronson E, Anand M, Healy P, George DJ, McNamara MA, Armstrong AJ. Expression of immune checkpoints (ICs) on circulating tumor cells (CTCs) in men with metastatic prostate cancer (mPC). Journal of Clinical Oncology. 36: 5059-5059. DOI: 10.1200/JCO.2018.36.15_SUPPL.5059 |
0.361 |
|
| 2018 |
Sartor AO, Higano CS, Cooperberg MR, Vogelzang NJ, Dakhil SR, Pieczonka CM, Vacirca J, Concepcion RS, Tutrone RF, Nordquist LT, Olsson CA, Penson DF, Schnadig I, Bailen JL, Mehlhaff B, ... ... Armstrong AJ, et al. Sipuleucel-T (sip-T) overall survival (OS) and clinical outcomes by baseline (BL) prostate-specific antigen (PSA) quartiles in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROCEED registry. Journal of Clinical Oncology. 36: 5041-5041. DOI: 10.1200/JCO.2018.36.15_SUPPL.5041 |
0.43 |
|
| 2018 |
Autio KA, Antonarakis ES, Mayer TM, Vaishampayan UN, Shevrin DH, Harrison MR, Tagawa ST, Milowsky MI, Graff JN, Beer TM, Balar AV, Stein M, Heath EI, Armstrong AJ, Paller CJ, et al. Phase 2, randomized, 3-arm study of abiraterone acetate and prednisone (AAP), AAP plus degarelix (AAP+D), and degarelix (D) alone for patients (pts) with biochemically-recurrent prostate cancer (PC) following radical prostatectomy (RP). Journal of Clinical Oncology. 36: 5016-5016. DOI: 10.1200/Jco.2018.36.15_Suppl.5016 |
0.373 |
|
| 2018 |
Freedland S, Aronson W, Howard L, Smith J, Smith M, Stout J, Allen J, George D, Armstrong A, Inman B, Lin P. PD14-12 SECONDARY OUTCOMES OF A PROSPECTIVE RANDOMIZED TRIAL OF DIETARY CARBOHYDRATE RESTRICTION FOR MEN INITIATING ANDROGEN DEPRIVATION THERAPY: CARBOHYDRATE AND PROSTATE STUDY I (CAPS1) Journal of Urology. 199. DOI: 10.1016/J.JURO.2018.02.798 |
0.329 |
|
| 2018 |
Fantony JJ, Howard LE, Csizmadi I, Armstrong AJ, Lark AL, Galet C, Aronson WJ, Freedland SJ. MP35-16 IS KI67 PROGNOSTIC FOR AGGRESSIVE PROSTATE CANCER? A MULTICENTER REAL-WORLD STUDY Journal of Urology. 199. DOI: 10.1016/J.JURO.2018.02.1129 |
0.43 |
|
| 2018 |
Koontz B, Hoffman K, Healy P, George D, Harrison M, Zhang T, Lee W, Berry W, Pugh T, Bratt L, Hobbs B, Halabi S, Corn P, Armstrong A, Shobe K, et al. Two Year Outcomes of Short-Term Potent Androgen Blockade and Definitive Radiation for Intermediate to High Risk Localized Prostate Cancer International Journal of Radiation Oncology*Biology*Physics. 102: S100. DOI: 10.1016/J.Ijrobp.2018.06.256 |
0.34 |
|
| 2017 |
Humeniuk MS, Gupta RT, Healy P, McNamara M, Ramalingam S, Harrison M, George D, Zhang T, Wu Y, Armstrong AJ. Platinum sensitivity in metastatic prostate cancer: does histology matter? Prostate Cancer and Prostatic Diseases. PMID 29230006 DOI: 10.1038/S41391-017-0017-6 |
0.43 |
|
| 2017 |
Armstrong AJ, Antonarakis ES, Taplin ME, Kelly WK, Beltran H, Fizazi K, Dahut WL, Shore N, Slovin S, George D, Carducci MA, Corn P, Danila D, Dreicer R, Heath E, et al. Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 29088323 DOI: 10.1093/annonc/mdx648 |
0.387 |
|
| 2017 |
Zhang T, Armstrong AJ. The Who, What, and How of Cabazitaxel Treatment in Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017747931. PMID 28809609 DOI: 10.1200/JCO.2017.74.7931 |
0.431 |
|
| 2017 |
Zhu J, Tucker M, Wang E, Grossman JS, Armstrong AJ, George DJ, Zhang T. Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. PMID 28780018 DOI: 10.1016/j.clgc.2017.07.005 |
0.404 |
|
| 2017 |
Taplin ME, Armstrong AJ, Lin P, Krivoshik A, Phung, Parli T, Tombal B, Beer TM. Clinical Outcomes of Chemotherapy-Naïve Men with Metastatic Castration-Resistant Prostate Cancer and Low Baseline PSA Treated with Enzalutamide vs Placebo. The Journal of Urology. PMID 28736322 DOI: 10.1016/j.juro.2017.07.071 |
0.435 |
|
| 2017 |
Humeniuk MS, Zhang T, Armstrong AJ. Exploiting DNA damage without repair: The activity of platinum chemotherapy in BRCA-Mutated prostate cancers. Cancer. PMID 28608923 DOI: 10.1002/cncr.30806 |
0.308 |
|
| 2017 |
Armstrong AJ, Halabi S, Healy P, Alumkal JJ, Winters C, Kephart J, Bitting RL, Hobbs C, Soleau CF, Beer TM, Slottke R, Mundy K, Yu EY, George DJ. Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer. European Journal of Cancer (Oxford, England : 1990). PMID 28502694 DOI: 10.1016/j.ejca.2017.02.030 |
0.372 |
|
| 2017 |
Armstrong A, Bui C, Fitch K, Sawhney TG, Brown B, Flanders S, Balk M, Deangelis J, Chambers J. Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations. Current Medical Research and Opinion. 1-16. PMID 28318331 DOI: 10.1080/03007995.2017.1308919 |
0.385 |
|
| 2017 |
Sonpavde G, Armstrong AJ. Drug development in prostate cancer: time to embrace RECIST? The Lancet. Oncology. PMID 28283283 DOI: 10.1016/S1470-2045(17)30149-3 |
0.368 |
|
| 2017 |
Armstrong AJ, Saad F, Phung, Dmuchowski C, Shore ND, Fizazi K, Hirmand M, Forer D, Scher HI, Bono J. Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel. Cancer. PMID 28171710 DOI: 10.1002/Cncr.30587 |
0.463 |
|
| 2017 |
Ramalingam S, Humeniuk MS, Hu R, Rasmussen J, Healy P, Wu Y, Harrison MR, Armstrong AJ, George DJ, Zhang T. Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer. Urologic Oncology. PMID 28126272 DOI: 10.1016/J.Urolonc.2016.12.016 |
0.439 |
|
| 2017 |
Bryce AH, Alumkal JJ, Armstrong A, Higano CS, Iversen P, Sternberg CN, Rathkopf D, Loriot Y, de Bono J, Tombal B, Abhyankar S, Lin P, Krivoshik A, Phung D, Beer TM. Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. Prostate Cancer and Prostatic Diseases. PMID 28117385 DOI: 10.1038/pcan.2016.71 |
0.424 |
|
| 2017 |
Humeniuk MS, Gupta RT, McNamara MA, Ramalingam S, Harrison MR, George DJ, Wu Y, Healy P, Armstrong AJ. Association of neuroendocrine phenotype with platinum chemotherapy outcomes in men with metastatic prostate cancer. Journal of Clinical Oncology. 35: e16532-e16532. DOI: 10.1200/Jco.2017.35.15_Suppl.E16532 |
0.404 |
|
| 2017 |
Gjyrezi A, Galletti G, Strati A, Kim S, Lianidou E, Nanus DM, Luo J, Antonarakis E, Tagawa ST, Armstrong A, Giannakakou P. Abstract 2736: A digital droplet PCR assay for the quantitation of androgen receptor and splice variant expression in CTCs from metastatic castration resistant prostate cancer patients Cancer Research. 77: 2736-2736. DOI: 10.1158/1538-7445.Am2017-2736 |
0.33 |
|
| 2017 |
Armstrong A, Lin P, Higano C, Iversen P, Sternberg C, Tombal B, Phung D, Parli T, Krivoshik A, Beer T. Prognostic associations of prostate-specific antigen (PSA) decline with survival, radiographic response and progression in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide Annals of Oncology. 28: v270-v271. DOI: 10.1093/ANNONC/MDX370.004 |
0.454 |
|
| 2016 |
Armstrong AJ, Humeniuk MS, Healy P, Szmulewitz R, Winters C, Kephart J, Harrison MR, Martinez E, Mundy K, Halabi S, George D. Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial. The Prostate. PMID 27862097 DOI: 10.1002/Pros.23277 |
0.437 |
|
| 2016 |
Ramalingam S, Eisenberg A, Foo WC, Freedman J, Armstrong AJ, Moss LG, Harrison MR. Treatment-related neuroendocrine prostate cancer resulting in Cushing's syndrome. International Journal of Urology : Official Journal of the Japanese Urological Association. PMID 27766686 DOI: 10.1111/Iju.13225 |
0.375 |
|
| 2016 |
Gupta S, Li J, Kemeny G, Bitting RL, Beaver J, Somarelli J, Ware KE, Gregory S, Armstrong AJ. Whole genomic copy number alterations in circulating tumor cells from men with abiraterone or enzalutamide resistant metastatic castration-resistant prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27601596 DOI: 10.1158/1078-0432.Ccr-16-1211 |
0.328 |
|
| 2016 |
Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, Iversen P, Evans CP, Kim CS, Kimura G, Miller K, Saad F, Bjartell AS, Borre M, Mulders P, et al. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. European Urology. PMID 27477525 DOI: 10.1016/J.Eururo.2016.07.032 |
0.318 |
|
| 2016 |
Ware KE, Somarelli JA, Schaeffer D, Li J, Zhang T, Park S, Patierno SR, Freedman J, Garcia-Blanco MA, Armstrong AJ. Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer. Oncotarget. PMID 27409172 DOI: 10.18632/Oncotarget.10476 |
0.416 |
|
| 2016 |
Sternberg C, Armstrong A, Pili R, Ng S, Huddart R, Agarwal N, Khvorostenko D, Lyulko O, Brize A, Vogelzang N, Delva R, Harza M, Thanos A, James N, Werbrouck P, et al. Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27298414 DOI: 10.1200/Jco.2016.66.9697 |
0.402 |
|
| 2016 |
Antonarakis ES, Armstrong AJ, Dehm SM, Luo J. Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting. Prostate Cancer and Prostatic Diseases. PMID 27184811 DOI: 10.1038/Pcan.2016.17 |
0.433 |
|
| 2016 |
Evans CP, Higano CS, Keane T, Andriole G, Saad F, Iversen P, Miller K, Kim CS, Kimura G, Armstrong AJ, Sternberg CN, Loriot Y, de Bono J, Noonberg SB, Mansbach H, et al. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. European Urology. PMID 27006332 DOI: 10.1016/J.Eururo.2016.03.017 |
0.315 |
|
| 2016 |
Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, Tangen CM, Rosenthal M, Petrylak DP, Hussain M, Vogelzang NJ, Thompson IM, Chi KN, de Bono J, Armstrong AJ, et al. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26951312 DOI: 10.1200/Jco.2015.65.7270 |
0.434 |
|
| 2016 |
Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, ... ... Armstrong AJ, et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26903579 DOI: 10.1200/Jco.2015.64.2702 |
0.439 |
|
| 2016 |
Mehta AR, Armstrong AJ. Tasquinimod in the treatment of castrate-resistant prostate cancer - current status and future prospects. Therapeutic Advances in Urology. 8: 9-18. PMID 26834836 DOI: 10.1177/1756287215603558 |
0.484 |
|
| 2016 |
Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, Dunshee C, Wang F, Wu K, Krivoshik A, Phung, Higano CS. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26811535 DOI: 10.1200/JCO.2015.64.9285 |
0.454 |
|
| 2016 |
Armstrong AJ, Halabi S, Healy P, Lee WR, Koontz BF, Moul JW, Mundy K, Creel P, Wood S, Davis K, Carducci MA, Stein M, Hobbs C, Reimer B, Nguyen M, et al. A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy. Prostate Cancer and Prostatic Diseases. PMID 26754260 DOI: 10.1038/pcan.2015.59 |
0.359 |
|
| 2016 |
Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Kane CJ, Kawachi MH, Kuettel M, Lee RJ, et al. Prostate Cancer, Version 1.2016. Journal of the National Comprehensive Cancer Network : Jnccn. 14: 19-30. PMID 26733552 DOI: 10.6004/Jnccn.2016.0004 |
0.409 |
|
| 2016 |
Zhang T, Armstrong AJ. Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer. Current Oncology Reports. 18: 3. PMID 26700506 DOI: 10.1007/s11912-015-0490-9 |
0.354 |
|
| 2016 |
Tay KJ, Moul JW, Armstrong AJ. Management of Prostate Cancer in the Elderly. Clinics in Geriatric Medicine. 32: 113-132. PMID 26614864 DOI: 10.1016/j.cger.2015.08.001 |
0.397 |
|
| 2016 |
Armstrong AJ, Higano CS, Sartor AO, Vogelzang NJ, Berry WR, Penson DF, Kassabian V, Nordquist LT, Chang NN, LIll JS, Cooperberg MR. Changing characteristics of patients treated with sipuleucel-T (sip-T) over time: Real-world experience from the PROCEED registry. Journal of Clinical Oncology. 34: 320-320. DOI: 10.1200/jco.2016.34.2_suppl.320 |
0.311 |
|
| 2016 |
George DJ, Halabi S, Healy P, Gemberling S, Winters C, Mundy K, Harrison MR, Szmulewitz RZ, Armstrong AJ. Phase Ib trial of docetaxel, prednisone, and pazopanib, in men with metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 34: 275-275. DOI: 10.1200/Jco.2016.34.2_Suppl.275 |
0.446 |
|
| 2016 |
Armstrong AJ, Saad F, Shore ND, Fizazi K, Phung D, Dmuchowski CF, Hirmand M, Forer D, Scher HI, Bono JSD. Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM. Journal of Clinical Oncology. 34: 5062-5062. DOI: 10.1200/Jco.2016.34.2_Suppl.266 |
0.385 |
|
| 2016 |
Sternberg CN, Armstrong AJ, Pili R, Nederman T, Carducci MA. A Phase 3, randomized, double-blind, placebo-controlled study of tasquinimod (TASQ) in men with metastatic castration-resistant prostate cancer (mCRPC), secondary endpoints. Journal of Clinical Oncology. 34: 239-239. DOI: 10.1200/Jco.2016.34.2_Suppl.239 |
0.305 |
|
| 2016 |
Higano CS, Armstrong AJ, Cooperberg MR, Concepcion RS, Tutrone RF, Olsson CA, Pieczonka CM, Shore ND, Chang NN, LIll JS, Sartor AO. Analysis of the PROCEED registry by baseline prostate-specific antigen (PSA) quartiles: Preliminary analysis of real-world sipuleucel-T (sip-T) use. Journal of Clinical Oncology. 34: 193-193. DOI: 10.1200/JCO.2016.34.2_SUPPL.193 |
0.341 |
|
| 2016 |
Penson DF, Armstrong AJ, Concepcion RS, Wu K, Wang F, Krivoshik AP, Phung D, Higano CS. Sensitivity analyses for progression-free survival (PFS) and radiographic PFS (rPFS) from the phase II STRIVE trial comparing enzalutamide (ENZA) with bicalutamide (BIC) in men with castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology. 34: 169-169. DOI: 10.1200/JCO.2016.34.2_SUPPL.169 |
0.333 |
|
| 2016 |
Vogelzang NJ, Armstrong AJ, Higano CS, Sartor AO, Pieczonka CM, Concepcion RS, Tutrone RF, Olsson CA, Bailen JL, Penson DF, Chang NN, LIll JS, Tyler RC, Cooperberg MR. Treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) in oncology (ONC) urology (URO) practices: Data from the PROCEED registry. Journal of Clinical Oncology. 34: e16503-e16503. DOI: 10.1200/JCO.2016.34.15_SUPPL.E16503 |
0.406 |
|
| 2016 |
Ramalingam S, Humeniuk MS, Hu R, Rasmussen J, Healy P, Wu Y, Harrison MR, Armstrong AJ, George DJ, Zhang T. PSA response in black and white patients treated with abiraterone acetate (AA) for metastatic castrate-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 34: 5033-5033. DOI: 10.1200/Jco.2016.34.15_Suppl.5033 |
0.428 |
|
| 2016 |
Beltran H, Danila D, Montgomery B, Szmulewitz R, Vaishampayan U, Armstrong A, Stein M, Hoimes C, Pinski J, Scher H, Puca L, Bareja R, Wong W, Rubin M, Mosquera J, et al. A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC) Annals of Oncology. 27: vi565. DOI: 10.1093/ANNONC/MDW435.21 |
0.375 |
|
| 2016 |
Stenzl A, Krivoshik A, Baron B, Hirmand M, Armstrong A. Efficacy and safety of enzalutamide plus androgen deprivation therapy vs placebo plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: the ongoing ARCHES trial Annals of Oncology. 27: vi262. DOI: 10.1093/ANNONC/MDW372.51 |
0.396 |
|
| 2016 |
Bryce A, Alumkal J, Armstrong A, Higano C, Iversen P, Sternberg C, Rathkopf D, Loriot Y, de Bono J, Tombal B, Abhyankar S, Lin P, Krivoshik A, Phung D, Beer T. A post hoc analysis of radiographic progression with nonrising prostate-specific antigen in patients with metastatic castration-resistant prostate cancer (mCRPC) in the PREVAIL study Annals of Oncology. 27: vi258. DOI: 10.1093/ANNONC/MDW372.44 |
0.449 |
|
| 2016 |
Freedland S, Aronson W, Howard L, Smith J, Smith M, Stout J, Allen J, George D, Armstrong A, Inman B, Lin P. MP04-06 A PROSPECTIVE RANDOMIZED TRIAL OF DIETARY CARBOHYDRATE RESTRICTION FOR MEN INITIATING ANDROGEN DEPRIVATION THERAPY: CARBOHYDRATE AND PROSTATE STUDY I (CAPS1) Journal of Urology. 195. DOI: 10.1016/J.JURO.2016.02.1941 |
0.377 |
|
| 2015 |
Graff JN, Baciarello G, Armstrong AJ, Higano CS, Iversen P, Flaig TW, Forer D, Parli T, Phung D, Tombal B, Beer TM, Sternberg CN. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 26578735 DOI: 10.1093/annonc/mdv542 |
0.435 |
|
| 2015 |
Sonpavde G, Pond GR, Templeton AJ, Fandi A, Tombal B, Rosenthal M, Armstrong AJ, Petrylak DP. Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel. European Urology. PMID 26497922 DOI: 10.1016/j.eururo.2015.10.008 |
0.302 |
|
| 2015 |
Armstrong AJ, Healy P, Halabi S, Vollmer R, Lark A, Kemeny G, Ware K, Freedland SJ. Evaluation of an epithelial plasticity biomarker panel in men with localized prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 26458958 DOI: 10.1038/pcan.2015.46 |
0.414 |
|
| 2015 |
Li J, Armstrong AJ. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer. Clinical Advances in Hematology & Oncology : H&O. 13: 293-8. PMID 26352773 |
0.438 |
|
| 2015 |
Zhang T, Armstrong AJ. Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 4505-7. PMID 26307134 DOI: 10.1158/1078-0432.CCR-15-1613 |
0.457 |
|
| 2015 |
Hussain M, Rathkopf D, Liu G, Armstrong A, Kelly WK, Ferrari A, Hainsworth J, Joshi A, Hozak RR, Yang L, Schwartz JD, Higano CS. A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer. European Journal of Cancer (Oxford, England : 1990). 51: 1714-24. PMID 26082390 DOI: 10.1016/j.ejca.2015.05.019 |
0.362 |
|
| 2015 |
Li J, Gregory SG, Garcia-Blanco MA, Armstrong AJ. Using circulating tumor cells to inform on prostate cancer biology and clinical utility. Critical Reviews in Clinical Laboratory Sciences. 1-20. PMID 26079252 DOI: 10.3109/10408363.2015.1023430 |
0.449 |
|
| 2015 |
Armstrong AJ. Docetaxel for advanced prostate cancer: how early to start? The Lancet. Oncology. 16: 741-2. PMID 26028517 DOI: 10.1016/S1470-2045(15)00012-1 |
0.427 |
|
| 2015 |
Armstrong AJ. New treatment options in castration-resistant prostate cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 13: 690-3. PMID 25995432 |
0.411 |
|
| 2015 |
Stover JT, Moore RA, Davis K, Harrison MR, Armstrong AJ. Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. 18: 161-6. PMID 25777155 DOI: 10.1038/Pcan.2015.7 |
0.419 |
|
| 2015 |
Zhang T, Dhawan MS, Healy P, George DJ, Harrison MR, Oldan J, Chin B, Armstrong AJ. Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 13: 392-9. PMID 25708161 DOI: 10.1016/J.Clgc.2015.01.004 |
0.372 |
|
| 2015 |
Armstrong AJ, Halabi S. Making progress on progression in metastatic prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1322-4. PMID 25667271 DOI: 10.1200/JCO.2014.59.4283 |
0.438 |
|
| 2015 |
Bitting RL, Healy P, Halabi S, George DJ, Goodin M, Armstrong AJ. Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer. Urologic Oncology. 33: 110.e1-9. PMID 25595577 DOI: 10.1016/j.urolonc.2014.09.002 |
0.429 |
|
| 2015 |
Zhang T, Zhu J, George DJ, Armstrong AJ. Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer. Expert Opinion On Pharmacotherapy. 16: 473-85. PMID 25534660 DOI: 10.1517/14656566.2015.995090 |
0.44 |
|
| 2015 |
Sonpavde G, Wang CG, Galsky MD, Oh WK, Armstrong AJ. Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC). Bju International. 116: 17-29. PMID 25046451 DOI: 10.1111/bju.12867 |
0.383 |
|
| 2015 |
Harrison MR, Armstrong AJ. Burden of disease matters when it comes to systemic therapy for prostate cancer. European Urology. 67: 448-50. PMID 24612662 DOI: 10.1016/J.Eururo.2014.02.032 |
0.414 |
|
| 2015 |
Armstrong AJ, Halabi S, Healy P, Lee R, Koontz BF, Moul JW, Mundy K, Creel P, Wood SY, Davis K, Reimer B, Nguyen M, Spitz AN, Bratt E, Kim S, et al. A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy (RT) in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP). Journal of Clinical Oncology. 33: 35-35. DOI: 10.1200/Jco.2015.33.7_Suppl.35 |
0.409 |
|
| 2015 |
Tutrone RF, Ahaghotu C, Armstrong AJ, Higano CS, Cooperberg MR, Belkoff LH, Olsson CA, Goel S, Tyler RC, LIll JS, Gray TE, McCoy C, Sartor AO. Characteristics of African Americans (AAs) treated with sipuleucel-T (sip-T): Comparison of clinical trial and real-world experience. Journal of Clinical Oncology. 33: 272-272. DOI: 10.1200/JCO.2015.33.7_SUPPL.272 |
0.356 |
|
| 2015 |
Armstrong AJ, Halabi S, Healy P, Alumkal JJ, Yu EY, Winters C, Hobbs C, Soleau C, Slottke R, Mundy K, George DJ. Phase II trial of the PI3 kinase inhibitor BKM120 with or without enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 33: 5025-5025. DOI: 10.1200/jco.2015.33.15_suppl.5025 |
0.402 |
|
| 2015 |
Morris MJ, Hilden P, Gleave ME, Armstrong AJ, Carducci MA, Saad F, Dayan ES, Filipenko J, Acosta I, Heller G, Scher HI. Efficacy analysis of a phase III study of androgen deprivation therapy (ADT) +/- docetaxel (D) for men with biochemical relapse (BCR) after prostatectomy. Journal of Clinical Oncology. 33: 5011-5011. DOI: 10.1200/Jco.2015.33.15_Suppl.5011 |
0.417 |
|
| 2015 |
Scher HI, Morris MJ, Stadler WM, Higano CS, Halabi S, Smith MR, Basch EM, Fizazi K, Ryan CJ, Antonarakis ES, Corn PG, Liu G, De Bono JS, Schwartz LH, Beer TM, ... ... Armstrong AJ, et al. The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology. 33: 5000-5000. DOI: 10.1200/JCO.2015.33.15_SUPPL.5000 |
0.445 |
|
| 2015 |
Ware KE, Schaeffer D, Zhang T, Garcia-Blanco MA, Armstrong AJ. Abstract 1847: AR-V7 regulation during epithelial plasticity Cancer Research. 75: 1847-1847. DOI: 10.1158/1538-7445.Am2015-1847 |
0.315 |
|
| 2015 |
Penson D, Armstrong A, Concepcion R, Agarwal N, Wang F, Wu K, Amelsberg A, Phung D, Higano C. PII-LBA10 A MULTICENTER PHASE 2 STUDY OF ENZALUTAMIDE (ENZA) VERSUS BICALUTAMIDE (BIC) IN MEN WITH NONMETASTATIC (M0) OR METASTATIC (M1) CASTRATION-RESISTANT PROSTATE CANCER (CRPC): THE STRIVE TRIAL Journal of Urology. 193. DOI: 10.1016/J.JURO.2015.03.124 |
0.378 |
|
| 2015 |
Li J, Armstrong AJ. Prognostic and predictive biomarkers for castration resistant prostate cancer Biomarkers in Disease: Methods, Discoveries and Applications: Biomarkers in Cancer. 447-480. DOI: 10.1007/978-94-007-7681-4_13 |
0.436 |
|
| 2014 |
Bhavsar NA, Harrison MR, Howie LJ, Armstrong AJ, Davis K, Chen Q, Pupa MR, Abernethy A, George DJ, Hirsch BR. 1072PEXPERIENCE OF PATIENTS TREATED WITH SIPULEUCEL-T IN AN ACADEMIC SETTING. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv369-iv370. PMID 28171524 DOI: 10.1093/Annonc/Mdu342.25 |
0.364 |
|
| 2014 |
Armstrong AJ. In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet. Oncology (Williston Park, N.Y.). 28: 881, 883. PMID 25323615 |
0.432 |
|
| 2014 |
Armstrong AJ, Kaboteh R, Carducci MA, Damber JE, Stadler WM, Hansen M, Edenbrandt L, Forsberg G, Nordle Ö, Pili R, Morris MJ. Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC). Urologic Oncology. 32: 1308-16. PMID 25240761 DOI: 10.1016/J.Urolonc.2014.08.006 |
0.405 |
|
| 2014 |
Stewart SB, Moul JW, Polascik TJ, Koontz BF, Robertson CN, Freedland SJ, George DJ, Lee WR, Armstrong AJ, Bañez LL. Does the multidisciplinary approach improve oncological outcomes in men undergoing surgical treatment for prostate cancer? International Journal of Urology : Official Journal of the Japanese Urological Association. 21: 1215-9. PMID 25041422 DOI: 10.1111/iju.12561 |
0.386 |
|
| 2014 |
Armstrong AJ. Biomarkers in castration-resistant prostate cancer. Clinical Advances in Hematology & Oncology : H&O. 12: 115-8. PMID 24892256 |
0.421 |
|
| 2014 |
Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. The New England Journal of Medicine. 371: 424-33. PMID 24881730 DOI: 10.1056/Nejmoa1405095 |
0.436 |
|
| 2014 |
Ware KE, Garcia-Blanco MA, Armstrong AJ, Dehm SM. Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. Endocrine-Related Cancer. 21: T87-T103. PMID 24859991 DOI: 10.1530/Erc-13-0470 |
0.347 |
|
| 2014 |
Aggarwal R, Zhang T, Small EJ, Armstrong AJ. Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. Journal of the National Comprehensive Cancer Network : Jnccn. 12: 719-26. PMID 24812138 DOI: 10.6004/jnccn.2014.0073 |
0.441 |
|
| 2014 |
Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, et al. Prostate cancer, version 2.2014. Journal of the National Comprehensive Cancer Network : Jnccn. 12: 686-718. PMID 24812137 DOI: 10.6004/Jnccn.2014.0072 |
0.421 |
|
| 2014 |
Sonpavde G, Pond GR, Armstrong AJ, Clarke SJ, Vardy JL, Templeton AJ, Wang SL, Paolini J, Chen I, Chow-Maneval E, Lechuga M, Smith MR, Michaelson MD. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Clinical Genitourinary Cancer. 12: 317-24. PMID 24806399 DOI: 10.1016/j.clgc.2014.03.005 |
0.424 |
|
| 2014 |
Younis IR, George DJ, McManus TJ, Hurwitz H, Creel P, Armstrong AJ, Yu JJ, Bacon K, Hobbs G, Peer CJ, Petros WP. Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer. Cancer Chemotherapy and Pharmacology. 73: 991-7. PMID 24619498 DOI: 10.1007/S00280-014-2432-X |
0.381 |
|
| 2014 |
Bitting RL, Schaeffer D, Somarelli JA, Garcia-Blanco MA, Armstrong AJ. The role of epithelial plasticity in prostate cancer dissemination and treatment resistance. Cancer Metastasis Reviews. 33: 441-68. PMID 24414193 DOI: 10.1007/S10555-013-9483-Z |
0.452 |
|
| 2014 |
Sonpavde G, Pond GR, Armstrong AJ, Galsky MD, Leopold L, Wood BA, Wang SL, Paolini J, Chen I, Chow-Maneval E, Mooney DJ, Lechuga M, Smith MR, Michaelson MD. Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer. Bju International. 114: E25-31. PMID 24298897 DOI: 10.1111/bju.12589 |
0.457 |
|
| 2014 |
Armstrong AJ. New treatments for men with castration-resistant prostate cancer: Can we move from small steps to giant leaps? European Urology. 65: 300-302. PMID 24054873 DOI: 10.1016/j.eururo.2013.08.059 |
0.425 |
|
| 2014 |
Li J, Beaver J, Bitting RL, Gregory S, Armstrong AJ. Genomic analysis of circulating tumor cells (CTCs) from men with metastatic castration resistant prostate cancer (mCRPC) in the context of enzalutamide therapy. Journal of Clinical Oncology. 32: 5042-5042. DOI: 10.1200/Jco.2014.32.4_Suppl.65 |
0.342 |
|
| 2014 |
Armstrong AJ, Bitting RL, Kemeny G, George DJ. Evidence for circulating tumor cell (CTC) alkaline phosphatase (AP) expression in men with bone-metastatic castration-resistant prostate cancer (CRPC) during abiraterone acetate treatment. Journal of Clinical Oncology. 32: 178-178. DOI: 10.1200/jco.2014.32.4_suppl.178 |
0.354 |
|
| 2014 |
Zhang T, Dhawan MS, Healy P, George DJ, Oldan J, Chin B, Armstrong AJ. Clinical benefit of docetaxel or enzalutamide after progression on first-line abiraterone acetate and prednisone in men with metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 32: e16031-e16031. DOI: 10.1200/JCO.2014.32.15_SUPPL.E16031 |
0.448 |
|
| 2014 |
Morris MJ, Gleave ME, Armstrong AJ, Carducci MA, Saad F, Lacuna KP, Scher HI. A randomized, open label, multicenter, phase 3, 2-arm study of androgen deprivation with leuprolide (L), ± docetaxel (D) for clinically asymptomatic prostate cancer (PC) subjects with a rising PSA following definitive local therapy: Safety results. Journal of Clinical Oncology. 32: 5022-5022. DOI: 10.1200/Jco.2014.32.15_Suppl.5022 |
0.372 |
|
| 2014 |
Armstrong AJ, Tombal B, Sternberg CN, Higano CS, Rathkopf DE, Loriot Y, Saad F, Joshua AM, Bono JSD, Venner PM, Carles J, Mainwaring PN, Evans CP, Noonberg SB, Mansbach HH, et al. Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 32: 5007-5007. DOI: 10.1200/Jco.2014.32.15_Suppl.5007 |
0.408 |
|
| 2014 |
Halabi S, Kelly WK, Zhou H, Armstrong AJ, Quinn D, Fizazi K, Solomon NC, Tannock I, Petrylak DP, Morris MJ, Small EJ. The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials. Journal of Clinical Oncology. 32: 5002-5002. DOI: 10.1200/Jco.2014.32.15_Suppl.5002 |
0.353 |
|
| 2014 |
Shuman J, Armstrong A. Safety and Efficacy of Enzalutamide in Men with Metastatic Prostate Cancer: The PREVAIL Trial Md Conference Express. 14: 20-21. DOI: 10.1177/155989771414013 |
0.419 |
|
| 2014 |
Evans C, Higano CS, Keane T, Andriole G, Saad F, Iversen P, Miller K, Kim C, Kimura G, Armstrong A, Sternberg C, Loriot Y, Bono Jd, Mansbach H, Noonberg S, et al. Pi-05 Late-Breaking Abstract: The Prevail Study: Primary And Non-Visceral / Visceral Disease Subgroup Results For Enzalutamide-Treated Men With Metastatic Prostate Cancer (Mpc) That Had Progressed On Adt The Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.2577 |
0.433 |
|
| 2014 |
Cooperberg M, Sartor O, Armstrong A, Pieczonka C, Concepcion R, Kassabian V, Tutrone R, Bailen J, Shore N, Karsh L, Hertzman B, Penson D, McCoy C, Sandler A, Tyler R, et al. MP70-02 TREATMENT PRACTICE PATTERNS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PRIOR TO RECEIVING SIPULEUCEL-T: DATA FROM PROCEED Journal of Urology. 191. DOI: 10.1016/J.JURO.2014.02.2201 |
0.397 |
|
| 2013 |
Bardia A, Blackford AL, Lin J, Armstrong AJ, King S, Rudek MA, Yegnasubramanian ST, Carducci MA. A prostate cancer clinical trials consortium trial of disulfiram (D) in men with nonmetastatic recurrent prostate cancer (PCa). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 219. PMID 28137035 DOI: 10.1200/Jco.2013.31.6_Suppl.219 |
0.401 |
|
| 2013 |
Lin CY, Small EJ, Armstrong AJ, Kaplan EB, Petrylak DP, Sternberg CN, Shen L, Oudard S, De Bono JS, Sartor AO. A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 24. PMID 28136957 DOI: 10.1200/Jco.2013.31.6_Suppl.24 |
0.333 |
|
| 2013 |
Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev V, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, De Bono JS, et al. Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: LBA8. PMID 28136933 DOI: 10.1200/Jco.2013.31.6_Suppl.Lba8 |
0.313 |
|
| 2013 |
George DJ, Armstrong AJ, Harrison MR. Highlights in advanced prostate cancer from the 2013 American Urological Association Annual Meeting and the 2013 American Society of Clinical Oncology Annual Meeting: commentary. Clinical Advances in Hematology & Oncology : H&O. 11: 16-22. PMID 25856023 |
0.342 |
|
| 2013 |
Zhang T, Armstrong AJ. Clinical phenotypes of castration-resistant prostate cancer. Clinical Advances in Hematology & Oncology : H&O. 11: 707-18. PMID 24896544 |
0.423 |
|
| 2013 |
Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kawachi MH, Kuettel M, Lee RJ, Macvicar GR, et al. Prostate cancer, version 1.2014. Journal of the National Comprehensive Cancer Network : Jnccn. 11: 1471-9. PMID 24335682 DOI: 10.6004/Jnccn.2013.0174 |
0.456 |
|
| 2013 |
Stoyanova T, Cooper AR, Drake JM, Liu X, Armstrong AJ, Pienta KJ, Zhang H, Kohn DB, Huang J, Witte ON, Goldstein AS. Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells. Proceedings of the National Academy of Sciences of the United States of America. 110: 20111-6. PMID 24282295 DOI: 10.1073/Pnas.1320565110 |
0.314 |
|
| 2013 |
Armstrong AJ, Häggman M, Stadler WM, Gingrich JR, Assikis V, Polikoff J, Damber JE, Belkoff L, Nordle Ö, Forsberg G, Carducci MA, Pili R. Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6891-901. PMID 24255071 DOI: 10.1158/1078-0432.Ccr-13-1581 |
0.417 |
|
| 2013 |
Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev VB, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, et al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. The Lancet. Oncology. 14: 1307-16. PMID 24211163 DOI: 10.1016/S1470-2045(13)70479-0 |
0.439 |
|
| 2013 |
Halabi S, Lin CY, Small EJ, Armstrong AJ, Kaplan EB, Petrylak D, Sternberg CN, Shen L, Oudard S, de Bono J, Sartor O. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. Journal of the National Cancer Institute. 105: 1729-37. PMID 24136890 DOI: 10.1093/Jnci/Djt280 |
0.378 |
|
| 2013 |
Halabi S, Armstrong AJ, Sartor O, de Bono J, Kaplan E, Lin CY, Solomon NC, Small EJ. Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 3944-50. PMID 24101043 DOI: 10.1200/Jco.2013.50.3201 |
0.449 |
|
| 2013 |
Schweizer MT, Lin J, Blackford A, Bardia A, King S, Armstrong AJ, Rudek MA, Yegnasubramanian S, Carducci MA. Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer. Prostate Cancer and Prostatic Diseases. 16: 357-61. PMID 23958896 DOI: 10.1038/Pcan.2013.28 |
0.407 |
|
| 2013 |
Armstrong AJ, Shen T, Halabi S, Kemeny G, Bitting RL, Kartcheske P, Embree E, Morris K, Winters C, Jaffe T, Fleming M, George DJ. A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer. Clinical Genitourinary Cancer. 11: 397-406. PMID 23830964 DOI: 10.1016/j.clgc.2013.05.007 |
0.433 |
|
| 2013 |
Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 1802-7. PMID 23585511 DOI: 10.1093/annonc/mdt138 |
0.427 |
|
| 2013 |
Bitting RL, Armstrong AJ. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer Endocrine-Related Cancer. 20. PMID 23456430 DOI: 10.1530/ERC-12-0394 |
0.371 |
|
| 2013 |
Bitting RL, Armstrong AJ. Potential predictive biomarkers for individualizing treatment for men with castration-resistant prostate cancer Cancer Journal (United States). 19: 25-33. PMID 23337754 DOI: 10.1097/PPO.0b013e31827e0b9c |
0.357 |
|
| 2013 |
Harrison MR, Wong TZ, Armstrong AJ, George DJ. Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Management and Research. 5: 1-14. PMID 23326203 DOI: 10.2147/Cmar.S25537 |
0.32 |
|
| 2013 |
Clarke JM, Armstrong AJ. Novel therapies for the treatment of advanced prostate cancer. Current Treatment Options in Oncology. 14: 109-26. PMID 23322116 DOI: 10.1007/s11864-012-0222-4 |
0.457 |
|
| 2013 |
Pond GR, Armstrong AJ, Galsky MD, Wood BA, Leopold L, Sonpavde G. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials. Urologic Oncology. 31: 1457-63. PMID 22552048 DOI: 10.1016/j.urolonc.2012.02.008 |
0.426 |
|
| 2013 |
Whang YE, Armstrong AJ, Rathmell WK, Godley PA, Kim WY, Pruthi RS, Wallen EM, Crane JM, Moore DT, Grigson G, Morris K, Watkins CP, George DJ. A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. Urologic Oncology. 31: 82-6. PMID 21396844 DOI: 10.1016/J.Urolonc.2010.09.018 |
0.41 |
|
| 2013 |
Bitting RL, Healy P, Halabi S, George DJ, Ko JH, Armstrong AJ. Evaluation of clinical phenotype, survival, and circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 31: 5031-5031. DOI: 10.1200/JCO.2013.31.15_SUPPL.5031 |
0.351 |
|
| 2013 |
Halabi S, Lin C, Small EJ, Armstrong AJ, Kaplan EB, Petrylak DP, Sternberg CN, Shen L, Oudard S, De Bono JS, Sartor AO. A prognostic model for predicting overall survival in metastatic castrate-resistant prostate cancer (mCRPC) men treated with second-line chemotherapy. Journal of Clinical Oncology. 31: 5011-5011. DOI: 10.1200/Jco.2013.31.15_Suppl.5011 |
0.309 |
|
| 2012 |
Pond GR, Armstrong AJ, Wood BA, Leopold LH, Galsky MD, Sonpavde G. Efficacy of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) exposed to prior ketoconazole (KC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 204. PMID 27967949 DOI: 10.1200/jco.2012.30.5_suppl.204 |
0.391 |
|
| 2012 |
Bitting RL, Armstrong AJ. Prognostic, predictive, and surrogate factors for individualizing treatment for men with castration-resistant prostate cancer. American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. 292-7. PMID 24451752 DOI: 10.14694/EdBook_AM.2012.32.292 |
0.393 |
|
| 2012 |
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England Journal of Medicine. 367: 1187-97. PMID 22894553 DOI: 10.1056/Nejmoa1207506 |
0.414 |
|
| 2012 |
Pond GR, Armstrong AJ, Wood BA, Leopold L, Galsky MD, Sonpavde G. Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy. Bju International. 110: E461-8. PMID 22520631 DOI: 10.1111/j.1464-410X.2012.11148.x |
0.369 |
|
| 2012 |
Sonpavde G, Armstrong AJ. Objective evaluation of bone metastases in prostate cancer: To what end? European Urology. 62: 85-87. PMID 22402111 DOI: 10.1016/j.eururo.2012.02.021 |
0.353 |
|
| 2012 |
Armstrong AJ, Moul JW, George DJ. What to order from the prostate cancer treatment menu? Oncology (Williston Park, N.Y.). 26. PMID 22393801 |
0.402 |
|
| 2012 |
Peppercorn J, Armstrong A, Zaas DW, George D. Rationing in urologic oncology: lessons from sipuleucel-T for advanced prostate cancer. Urologic Oncology. 31: 1079-84. PMID 22305627 DOI: 10.1016/j.urolonc.2011.12.022 |
0.326 |
|
| 2012 |
Armstrong AJ, Eisenberger MA, Halabi S, Oudard S, Nanus DM, Petrylak DP, Sartor AO, Scher HI. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. European Urology. 61: 549-59. PMID 22099611 DOI: 10.1016/j.eururo.2011.11.009 |
0.42 |
|
| 2012 |
Stewart SB, Bañez LL, Robertson CN, Freedland SJ, Polascik TJ, Xie D, Koontz BF, Vujaskovic Z, Lee WR, Armstrong AJ, Febbo PG, George DJ, Moul JW. Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center. The Journal of Urology. 187: 103-8. PMID 22088334 DOI: 10.1016/J.Juro.2011.09.040 |
0.387 |
|
| 2012 |
Araujo JC, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE, Trudel GC, Paliwal P, Agrawal S, Logothetis CJ. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer. 118: 63-71. PMID 21976132 DOI: 10.1002/cncr.26204 |
0.436 |
|
| 2012 |
Pond GR, Armstrong AJ, Wood BA, Brookes M, Leopold L, Berry WR, de Wit R, Eisenberger MA, Tannock IF, Sonpavde G. Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. European Urology. 61: 363-9. PMID 21715086 DOI: 10.1016/J.Eururo.2011.06.034 |
0.442 |
|
| 2012 |
Sonpavde G, Pond GR, Berry WR, de Wit R, Armstrong AJ, Eisenberger MA, Tannock IF. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urologic Oncology. 30: 607-13. PMID 20888271 DOI: 10.1016/J.Urolonc.2010.07.002 |
0.408 |
|
| 2012 |
Bono JSD, Fizazi K, Saad F, Taplin M, Sternberg CN, Miller K, Mulders P, Chi KN, Armstrong AJ, Hirmand M, Selby B, Scher HI. Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor. Journal of Clinical Oncology. 30: 4519-4519. DOI: 10.1200/Jco.2012.30.15_Suppl.4519 |
0.342 |
|
| 2012 |
Halabi S, Armstrong AJ, Sartor AO, De Bono JS, Kaplan EB, Small EJ. Prostate-specific antigen decline (PSA) as a surrogate for overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) who failed first-line chemotherapy. Journal of Clinical Oncology. 30: 4515-4515. DOI: 10.1200/JCO.2012.30.15_SUPPL.4515 |
0.317 |
|
| 2012 |
Armstrong A, Gingrich J, Häggman M, Stadler W, Damber J, Belkoff L, Clark R, Brosman S, Nordle O, Forsberg G, Carducci M, Pili R. 126 Long term safety and efficacy in a randomized multicenter international phase II study of tasquinimod in chemotherapy naïve patients with metastatic castrate-resistant prostate cancer European Urology Supplements. 11: e126-e126a. DOI: 10.1016/S1569-9056(12)60125-0 |
0.382 |
|
| 2012 |
Sonpavde G, Pond G, Armstrong A, Galsky M, Wood B, Wang S, Paolini J, Lechuga M, Smith M, Michaelson M. Association of Progression by Prostate Cancer Working Group (PCWG)-2 Criteria and Survival in Metastatic Castration Resistant Prostate Cancer Annals of Oncology. 23: ix297-ix298. DOI: 10.1016/s0923-7534(20)33529-8 |
0.45 |
|
| 2012 |
Corman J, Dawson N, Hall S, Nabhan C, Ferrari A, Armstrong A, Murdock M, Stewart F, Sheikh N, Petrylak D. Openact: Phase 2, Open-Label Study of Sipuleucel-T in Metastatic Castrate-Resistant Prostate Cancer (MCRPC) Annals of Oncology. 23: ix311. DOI: 10.1016/s0923-7534(20)33504-3 |
0.402 |
|
| 2012 |
Carducci M, Armstrong A, Häggman M, Stadler W, Gingrich J, Assikis V, Forsberg G, Olsson A, Nordle Ö, Pili R. Tasquinimod Mechanism of Action Biomarkers: Correlation with PFS and Survival in Men with Metastatic Castrate Resistant Prostate Cancer Treated in a Randomized Phase 2 Trial Annals of Oncology. 23: ix303. DOI: 10.1016/S0923-7534(20)33477-3 |
0.436 |
|
| 2012 |
Armstrong AJ. Where does abiraterone fit into the metastatic prostate cancer treatment algorithm? Community Oncology. 9: 238-239. DOI: 10.1016/j.cmonc.2012.07.006 |
0.402 |
|
| 2011 |
George DJ, Halabi S, Zurita AJ, Creel P, Mundy K, Turnbull JD, Yenser Wood SE, Armstrong AJ, Varley RJ, Madden J, Moul JW. Investigator-initiated pilot study of sunitinib malate in patients with newly diagnosed prostate cancer prior to prostatectomy: A trial of the DoD/PCF Prostate Cancer Clinical Trials Consortium. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4664. PMID 28023877 DOI: 10.1200/jco.2011.29.15_suppl.4664 |
0.43 |
|
| 2011 |
Pond GR, Armstrong AJ, Wood BA, Brookes M, Leopold LH, Berry WR, De Wit R, Eisenberger MA, Tannock I, Sonpavde G. Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 cycles in men with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4582. PMID 28023307 DOI: 10.1200/Jco.2011.29.15_Suppl.4582 |
0.402 |
|
| 2011 |
Fleming MT, Pond GR, Armstrong AJ, Wood BA, Brookes M, Leopold LH, Matveev VB, Burke JM, Caton JR, Sonpavde G. Ability of serum alkaline phosphatase (ALP) changes to complement PSA changes and predict survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel and prednisone (DP). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e15019. PMID 28020589 DOI: 10.1200/jco.2011.29.15_suppl.e15019 |
0.36 |
|
| 2011 |
Sonpavde G, Pond GR, Berry WR, De Wit R, Eisenberger MA, Tannock I, Armstrong AJ. Association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 118. PMID 27968667 DOI: 10.1200/jco.2011.29.7_suppl.118 |
0.451 |
|
| 2011 |
Armstrong AJ, Haggman M, Stadler WM, Gingrich JR, Assikis VJ, Nordle O, Forsberg G, Carducci MA, Pili R. Phase II study of tasquinimod in chemotherapy-naive patients with metastatic castrate-resistant prostate cancer (CRPC): Safety and efficacy analysis including subgroups. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 126. PMID 27968532 DOI: 10.1200/Jco.2011.29.7_Suppl.126 |
0.384 |
|
| 2011 |
Pond GR, Armstrong AJ, Wood BA, Brookes M, Leopold LH, Burke JM, Caton JR, Fleming MT, Sonpavde G. Assessment of two prognostic risk group methods to predict outcomes with docetaxel-based therapy in men with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 185. PMID 27968482 DOI: 10.1200/jco.2011.29.7_suppl.185 |
0.377 |
|
| 2011 |
Armstrong AJ, Ferrari AC, Quinn DI. The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer Clinical Advances in Hematology &Amp; Oncology : H&Amp;O. 9. PMID 22407145 |
0.396 |
|
| 2011 |
Bitting RL, Armstrong AJ, George DJ. Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T? Clinical Medicine Insights. Oncology. 5: 325-32. PMID 22084621 DOI: 10.4137/CMO.S5977 |
0.432 |
|
| 2011 |
Pili R, Häggman M, Stadler WM, Gingrich JR, Assikis VJ, Björk A, Nordle O, Forsberg G, Carducci MA, Armstrong AJ. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4022-8. PMID 21931019 DOI: 10.1200/Jco.2011.35.6295 |
0.441 |
|
| 2011 |
Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, Herold CI, Marcom PK, George DJ, Garcia-Blanco MA. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Molecular Cancer Research : McR. 9: 997-1007. PMID 21665936 DOI: 10.1158/1541-7786.Mcr-10-0490 |
0.338 |
|
| 2011 |
Antonarakis ES, Armstrong AJ. Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer Prostate Cancer and Prostatic Diseases. 14: 192-205. PMID 21577234 DOI: 10.1038/pcan.2011.23 |
0.449 |
|
| 2011 |
Antonarakis ES, Armstrong AJ. Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer Prostate Cancer and Prostatic Diseases. 14: 206-218. PMID 21577233 DOI: 10.1038/pcan.2011.24 |
0.418 |
|
| 2011 |
Armstrong AJ, Freedland SJ, Garcia-Blanco M. Epithelial-mesenchymal transition in prostate cancer: Providing new targets for therapy Asian Journal of Andrology. 13: 179-180. PMID 21383677 DOI: 10.1038/Aja.2010.169 |
0.387 |
|
| 2011 |
Sonpavde G, Pond GR, Berry WR, de Wit R, Eisenberger MA, Tannock IF, Armstrong AJ. The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. Cancer. 117: 3963-71. PMID 21365623 DOI: 10.1200/Jco.2011.29.7_Suppl.118 |
0.452 |
|
| 2011 |
Bitting RL, Armstrong AJ, George DJ. Management options in advanced prostate cancer: What is the role for sipuleucel-T? Clinical Medicine Insights: Oncology. 5: 325-332. DOI: 10.4137/CMO.S5977 |
0.431 |
|
| 2010 |
Armstrong AJ, Netto GJ, Rudek MA, Halabi S, Wood DP, Creel PA, Mundy K, Davis SL, Wang T, Albadine R, Schultz L, Partin AW, Jimeno A, Fedor H, Febbo PG, et al. A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 3057-66. PMID 20501622 DOI: 10.1158/1078-0432.Ccr-10-0124 |
0.398 |
|
| 2010 |
Armstrong AJ, George DJ. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer Prostate Cancer and Prostatic Diseases. 13: 108-116. PMID 20066005 DOI: 10.1038/pcan.2009.62 |
0.428 |
|
| 2010 |
Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 203-11. PMID 20008841 DOI: 10.1158/1078-0432.Ccr-09-2514 |
0.441 |
|
| 2010 |
Armstrong AJ, Tannock IF, de Wit R, George DJ, Eisenberger M, Halabi S. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. European Journal of Cancer (Oxford, England : 1990). 46: 517-25. PMID 20005697 DOI: 10.1016/J.Ejca.2009.11.007 |
0.314 |
|
| 2010 |
Armstrong AJ, Kemeny G, Turnbull JD, Chao C, Winters C, Fesko YA, Bradley DA, Halabi S, George DJ, Garcia-Blanco M. Impact of temsirolimus and anti-androgen therapy on circulating tumor cell (CTC) biology in men with castration-resistant metastatic prostate cancer (CRPC): A phase II study. Journal of Clinical Oncology. 28: TPS249-TPS249. DOI: 10.1200/JCO.2010.28.15_SUPPL.TPS249 |
0.424 |
|
| 2010 |
Sankhala KK, Chiorean EG, Armstrong AJ, Borad MJ, Traynor AM, Gadgeel SM, Langmuir VK, Eng C, Kroll S, Burris H. Phase I/II study of TH-302 in combination with docetaxel in patients with solid tumors including NSCLC and castrate-resistant prostate cancer (CRPC). Journal of Clinical Oncology. 28: e13527-e13527. DOI: 10.1200/JCO.2010.28.15_SUPPL.E13527 |
0.39 |
|
| 2010 |
Pond GR, Sonpavde G, Berry WR, De Wit R, Armstrong AJ, Eisenberger MA, Tannock I. Use of changes in serum alkaline phosphatase to predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy: A retrospective analysis of the TAX327 trial. Journal of Clinical Oncology. 28: 4637-4637. DOI: 10.1200/Jco.2010.28.15_Suppl.4637 |
0.441 |
|
| 2010 |
Pili R, Haggman M, Stadler WM, Gingrich JR, Assikis VJ, Björk A, Forsberg G, Carducci MA, Armstrong AJ. A randomized, multicenter, international phase II study of tasquinimod in chemotherapy naïve patients with metastatic castrate-resistant prostate cancer (CRPC). Journal of Clinical Oncology. 28: 4510-4510. DOI: 10.1200/Jco.2010.28.15_Suppl.4510 |
0.432 |
|
| 2010 |
Zhang C, Zheng L, Zhang Z, Shi L, Armstrong AJ. The allocation of berths and quay cranes by using a sub-gradient optimization technique Computers and Industrial Engineering. 58: 40-50. DOI: 10.1016/J.Cie.2009.08.002 |
0.351 |
|
| 2009 |
Armstrong AJ, Halabi S, Tannock IF, George DJ, DeWit R, Eisenberger M. Development of risk groups in metastatic castration-resistant prostate cancer (mCRPC) to facilitate the identification of active chemotherapy regimens. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5137. PMID 27964425 DOI: 10.1200/Jco.2009.27.15_Suppl.5137 |
0.355 |
|
| 2009 |
Araujo J, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE, Trudel GC, Paliwal P, Agrawal S, Logothetis CJ. Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: A phase I/II study (CA180086). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5061. PMID 27962978 DOI: 10.1200/jco.2009.27.15_suppl.5061 |
0.443 |
|
| 2009 |
Netto G, Armstrong A, Wood D, Creel P, Partin A, Jimeno A, Rudek M, George D, Gurganus R, Carducci MA. Pharmacodynamic (PD) study of pre-prostatectomy rapamycin in men with advanced localized prostate cancer (PC): A DOD Prostate Cancer Clinical Trials Consortium Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5001. PMID 27962897 DOI: 10.1200/Jco.2009.27.15_Suppl.5001 |
0.416 |
|
| 2009 |
Armstrong AJ, Febbo PG. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature. The Oncologist. 14: 816-27. PMID 19684076 DOI: 10.1634/Theoncologist.2009-0043 |
0.446 |
|
| 2009 |
Armstrong AJ, Halabi S, de Wit R, Tannock IF, Eisenberger M. The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer Prostate Cancer and Prostatic Diseases. 12: 88-93. PMID 18574490 DOI: 10.1200/Jco.2008.26.15_Suppl.5074 |
0.326 |
|
| 2009 |
Araujo J, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick G, Trudel GC, Paliwal P, Logothetis CJ. 7028 Dasatinib and docetaxel combination treatment for patients with metastatic castration-resistant prostate cancer (CRPC): analysis of Study CA180–086 Ejc Supplements. 7: 415. DOI: 10.1016/S1359-6349(09)71406-5 |
0.446 |
|
| 2008 |
Armstrong AJ, Creel P, Turnbull J, Moore C, Jaffe TA, Haley S, Petros W, Yenser S, Gockerman JP, Sleep D, Hurwitz H, George DJ. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 6270-6. PMID 18829508 DOI: 10.1158/1078-0432.CCR-08-1085 |
0.402 |
|
| 2008 |
Armstrong AJ, George DJ. New drug development in metastatic prostate cancer Urologic Oncology: Seminars and Original Investigations. 26: 430-437. PMID 18593623 DOI: 10.1016/j.urolonc.2007.11.006 |
0.343 |
|
| 2008 |
Armstrong AJ, Garrett-Mayer EL, Eisenberger M. Re: Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. Journal of the National Cancer Institute. 100: 681-2; author reply . PMID 18445824 DOI: 10.1093/jnci/djn104 |
0.411 |
|
| 2008 |
Ramiah V, George DJ, Armstrong AJ. Clinical endpoints for drug development in prostate cancer Current Opinion in Urology. 18: 303-308. PMID 18382240 DOI: 10.1097/MOU.0b013e3282fb7807 |
0.427 |
|
| 2008 |
Chen FL, Armstrong AJ, George DJ. Cell signaling modifiers in prostate cancer Cancer Journal. 14: 40-45. PMID 18303482 DOI: 10.1097/PPO.0b013e318161d40f |
0.335 |
|
| 2008 |
Armstrong AJ, Halabi S, Tannock IF, Ronald d, Eisenberger MA. The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer Journal of Clinical Oncology. 26: 5074-5074. DOI: 10.1200/jco.2008.26.15_suppl.5074 |
0.367 |
|
| 2008 |
Whang YE, Moore CN, Armstrong AJ, Rathmell WK, Godley PA, Crane JM, Grigson GI, Morris K, Watkins CP, George DJ. A phase II trial of lapatinib in hormone refractory prostate cancer Journal of Clinical Oncology. 26: 16037-16037. DOI: 10.1200/Jco.2008.26.15_Suppl.16037 |
0.402 |
|
| 2007 |
Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 6396-403. PMID 17975152 DOI: 10.1158/1078-0432.Ccr-07-1036 |
0.348 |
|
| 2007 |
Armstrong AJ, Garrett-Mayer E, Ou Yang YC, Carducci MA, Tannock I, de Wit R, Eisenberger M. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 3965-70. PMID 17761981 DOI: 10.1200/Jco.2007.11.4769 |
0.402 |
|
| 2007 |
Eisenberger M, Garrett-Mayer ES, Yang YO, Wit Rd, Tannock I, Armstrong AJ. A multivariate prognostic nomogram incorporating PSA kinetics in hormone-refractory metastatic prostate cancer (HRPC) Journal of Clinical Oncology. 25: 5058-5058. DOI: 10.1200/Jco.2007.25.18_Suppl.5058 |
0.371 |
|
| 2006 |
Armstrong AJ, Carducci MA. New drugs in prostate cancer Current Opinion in Urology. 16: 138-145. PMID 16679849 DOI: 10.1097/01.mou.0000193390.69845.bb |
0.409 |
|
| 2006 |
Armstrong AJ, Eisenberger M. Does gonadotropin-releasing-hormone agonist therapy for prostate cancer increase the risk of fracture? Commentary Nature Clinical Practice Urology. 3: 246-247. DOI: 10.1038/ncpuro0462 |
0.3 |
|
| 2005 |
Armstrong AJ, Carducci MA. Chemotherapy for advanced prostate cancer: Results of new clinical trials and future studies Current Oncology Reports. 7: 220-227. PMID 15847714 DOI: 10.1007/S11912-005-0077-Y |
0.391 |
|
| Show low-probability matches. |